

Contents lists available at ScienceDirect

# American Journal of Emergency Medicine

journal homepage: www.elsevier.com/locate/ajem

# Prevalence of peri-intubation major adverse events among critically ill patients: A systematic review and meta analysis



Jessica Downing, MD<sup>a,\*</sup>, Isha Yardi<sup>b</sup>, Christine Ren, MD<sup>a</sup>, Stephanie Cardona, DO<sup>c</sup>, Manahel Zahid<sup>b</sup>, Kaitlyn Tang<sup>b</sup>, Vera Bzhilyanskaya<sup>b</sup>, Priya Patel<sup>d</sup>, Ali Pourmand, MD MPH<sup>e</sup>, Quincy K. Tran, MD PhD<sup>a,b,f</sup>

<sup>a</sup> Program in Trauma and Critical Care, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, United States of America

<sup>b</sup> Research Associate Program, Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, United States of America

<sup>c</sup> Department of Critical Care Medicine, The Mount Sinai Hospital, NY, New York, United States of America

<sup>d</sup> University of Maryland School of Medicine, Baltimore, MD, United States of America

e Department of Emergency Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States of America

<sup>f</sup> Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, United States of America

## ARTICLE INFO

Article history: Received 25 January 2023 Received in revised form 25 May 2023 Accepted 26 June 2023

Keywords: Emergency airway management Peri-intubation adverse events Intubation Adverse events Difficult airway

## ABSTRACT

*Background:* Peri-intubation major adverse events (MAEs) are potentially preventable and associated with poor patient outcomes. Critically ill patients intubated in Emergency Departments, Intensive Care Units or medical wards are at particularly high risk for MAEs. Understanding the prevalence and risk factors for MAEs can help physicians anticipate and prepare for the physiologically difficult airway.

*Methods:* We searched PubMed, Scopus, and Embase for prospective and retrospective observational studies and randomized control trials (RCTs) reporting peri-intubation MAEs in intubations occurring outside the operating room (OR) or post-anesthesia care unit (PACU). Our primary outcome was any peri-intubation MAE, defined as any hypoxia, hypotension/cardiovascular collapse, or cardiac arrest. Esophageal intubation and failure to achieve first-pass success were not considered MAEs. Secondary outcomes were prevalence of hypoxia, cardiac arrest, and cardiovascular collapse. We performed random-effects meta-analysis to identify the prevalence of each outcome and moderator analyses and meta-regressions to identify risk factors. We assessed studies' quality using the Cochrane Risk of Bias 2 tool and the Newcastle-Ottawa Scale.

*Results:* We included 44 articles and 34,357 intubations. Peri-intubation MAEs were identified in 30.5% of intubations (95% CI 25–37%). MAEs were more common in the intensive care unit (ICU; 41%, 95% CI 33–49%) than the Emergency Department (ED; 17%, 95% CI 12–24%). Intubation for hemodynamic instability was associated with higher rates of MAEs, while intubation for airway protection was associated with lower rates of MAEs. Fifteen percent (15%, 95% CI 11.5–19%) of intubations were complicated by hypoxia, 2% (95% CI 1–3.5%) by cardiac arrest, and 18% (95% CI 13–23%) by cardiovascular collapse.

*Conclusions:* Almost one in three patients intubated outside the OR and PACU experience a peri-intubation MAE. Patients intubated in the ICU and those with pre-existing hemodynamic compromise are at highest risk. Resuscitation should be considered an integral part of all intubations, particularly in high-risk patients.

© 2023 Elsevier Inc. All rights reserved.

## 1. Introduction

The importance of planning for and preempting peri-intubation adverse events is a core tenant of emergency and critical care medicine, summarized in the popular mantra "resuscitate before you intubate" and the concept of "resuscitation sequence intubation." Unlike the operating room, intubation in the Emergency Department (ED), intensive

E-mail address: jessica.downing@umm.edu (J. Downing).

care unit (ICU), or medical wards is most often prompted by an acute hemodynamic, respiratory, or neurologic decompensation [1,2]. Patients requiring emergency intubation have been described as having "physiologically difficult airways," as their pre-intubation physiologic derangements significantly increase their risk for peri-intubation adverse events [3,4]. Through the suppression of sympathomimetic and respiratory drives, neuromuscular blockade (NMB), and a rapid transition from negative- to non-physiologic positive-pressure ventilation, intubation has the potential to cause rapid cardiovascular or respiratory decline, particularly among patients with pre-existing hypoxia, hypotension, or acidosis [3]. Peri-intubation hypoxia and hypotension have

<sup>\*</sup> Corresponding author at: 22 S Greene St, Suite T3N45, Baltimore, MD 21201, United States of America.

been associated with higher rates of in-hospital mortality [5-8]. Physicians taking care of these critically ill patients are walking a thin line: lack of adequate preparation can be devastating, while excessive delay of a necessary intubation may contribute to respiratory acidosis and risk of aspiration and set the stage for hemodynamic collapse.

A clear understanding of the prevalence of various peri-intubation events and their risk factors is an essential component of the emergency and critical care medicine mental airway toolkit, and sets the foundation for effective and efficient pre-, peri- and post-intubation resuscitation and care. In 2011, the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult Airway Society found that 25% of major airway complications within the hospital setting occur in the ED or ICU [9]. They identified repeated instances of failure to identify high-risk patients and to plan for, recognize, and rapidly respond to adverse events, and identified these breakdowns in care as major contributors to avoidable complications and deaths.

In this systematic review and meta-analysis, we aim to evaluate the available evidence regarding peri-intubation major adverse events (MAE)—specifically, hypoxia, cardiovascular collapse, and cardiac arrest—quantify their prevalence, and identify relevant demographic and clinical factors and interventions most likely to increase or reduce patients' risk.

## 2. Methods

## 2.1. Search and selection criteria

We queried PubMED, Scopus, and Embase databases on October 6, 20 and again on September 4, 2022. The search terms were ((adverse AND events) OR (hypoxemia) OR (hypoxia) OR (desaturation) OR (hypotension) OR (cardiac AND arrest) OR ((hemodynamic OR cardiovascular) AND (collapse))) AND ((endotracheal AND intubation) OR (emergency AND airway AND management) OR (peri-intubation)). We included original studies (retrospective and prospective observational studies and randomized control trials) conducted among adult patients (≥18 years old) undergoing endotracheal intubation in the ED, ICU, or medical wards that reported any MAE within 30 min of endotracheal intubation. We included only articles published in English language. Studies were excluded if they did not establish clear criteria for MAE prior to data analysis, if they reported intubations or events occurring in the operating room (OR), procedural suites, or postanesthesia care unit (PACU), events considered to be related to general anesthesia, or if the studies focused on out-of-hospital intubations.

We excluded conference publications, isolated abstracts, case reports, and other systemic reviews and meta-analyses. We excluded post-hoc or subgroup analyses of larger studies, even they met our inclusion criteria, to prevent the inclusion of duplicate data. For studies using the same database or hospital cohorts with overlapping inclusion criteria and years of data collection, we selected those with more patients, more granular reporting of adverse events, or those that reported on more recent data. We screened cited studies for potential inclusion but did not contact authors for additional data or information.

Two authors independently screened each abstract for inclusion; any disagreements were resolved by a third senior author. This process was repeated for full text screening. Two investigators had to agree that each study should proceed to the next step before it could do so. All screening was conducted through Covidence (Veritas Health Innovation, Melbourne AU). This study was conducted in accordance with the PRISMA (Preferred Reporting Items for Systemic Reviews and Meta-Analyses) 2020 statement [10], and it was registered with PROSPERO (CRD42022342134).

# 2.2. Outcomes of interest

Our primary outcome of interest was the prevalence of composite peri-intubation MAE, as it was defined by the authors of included studies. We selected this outcome to provide clinicians the most complete "birds-eye" view of patient risk at the time of intubation. "Peri-intubation" was defined as an event occurring after administration of sedating medications for intubation and up to 30 min following intubation. We specifically examined rates of peri-intubation cardiovascular collapse (indicated by hypotension with a systolic blood pressure (SBP) < 90 mmHg, mean arterial pressure (MAP) < 65 mmHg, requirement for new or increased vasopressors or bolus of intravenous fluids (IVF) to maintain SBP or MAP above the desired range, or as defined by study authors), hypoxia (indicated by pulse oximetry < 90% or as defined by study authors), and cardiac arrest. We separately examined the prevalence of peri-intubation hypoxia, cardiac arrest, and cardiovascular collapse as our secondary outcomes. We did not consider failure of first-pass intubation success or esophageal intubation to be a MAE.

# 2.3. Quality assessment

Two authors assessed the quality of each study; any disagreements were resolved *via* discussion between the two authors or by a third senior author. We reported the final results from the consensus of the involved investigators. All studies were screened using either the Cochrane Risk of Bias 2 tool [11] or the Newcastle-Ottawa scale [12] The Cochrane Risk of Bias 2 tool assesses randomized control trials (RCTs) for potential bias in patient randomization, protocol deviations, measurement and reporting of outcomes, and treatment of missing data. If any single domain is rated as having any risk of bias, the overall study is rated as having risk of bias. The Newcastle-Ottawa scale assesses observational studies based on selection of cohort, comparability of groups, and quality of outcomes. Using the Newcastle-Ottawa scale, we rated studies' quality as high (rated as  $\geq 7$  on a scale from 0 to 9), moderate (4–6), or low ( $\leq 3$ ). We assessed for heterogeneity using the  $P^2$  statistic and the Cochrane Q statistic.

## 2.4. Data extraction

Data from each study was extracted independently by two authors into a standardized Microsoft Excel spreadsheet (MicrosoftCorp, Redmond WA), and subsequently compared for consistency. Discrepancies were resolved by a third senior author. All reported data reflects the consensus of the investigators who performed data collection. We collected data regarding patient age and body mass index (BMI), location of intubation (ED, ICU, or medical floor), reason for intubation, clinical status at the time of intubation (reflected by patient vital signs and pre-intubation vasopressor use), mode of preoxygenation and induction medications used, and peri-intubation MAEs.

## 2.5. Statistical analysis

We reported categorical variables as percentages and continuous variables as mean (standard deviation [SD]). Continuous variables reported in individual studies as median (interquartile range [IQR]) were converted to mean (SD) [13]. The prevalence of MAE was reported as percentage and 95% Confidence Interval (CI). Primary and secondary outcomes across our pooled patient population were estimated using random-effects models. Studies reporting two similar outcomes were eligible for meta-analysis. Included studies were assumed to be a random sample from a universe of potential studies [14-18]. The "true" prevalence of MAE can be expected to fall anywhere within the confidence interval reported here [14,16,18-26]. We used multivariable meta-regressions to evaluate the association between continuous and categorical variables and rates of primary and secondary outcomes. Variables for the multivariable meta-regression were selected *a priori*. They included patients' demographics and clinical data.

Heterogeneity was assessed using the Cochrane Q statistic and the  $l^2$  statistic. The Q statistic tests against the null hypothesis that all studies in the analysis share a common effect size. If all studies shared the same true effect size, the expected value of Q would be equal to the degrees of

## J. Downing, I. Yardi, C. Ren et al.

freedom (the number of studies minus 1). The  $l^2$  statistic provides an estimate of the percentage of observed variance that is reflective of true variance in effect size rather than sampling error. We calculated tau (the standard deviation of true effect size between included studies) and tau-squared (the variance of true effect size in included studies) to further characterize heterogeneity. This allowed us to calculate prediction intervals to generalize our findings to a broader population. Prediction intervals suggest a range in which the true effect size in 95% of all comparable populations could be expected to fall. We calculated prediction intervals assuming true effect sizes were normally distributed.

We performed moderator analyses with categorical variables and studies' characteristics to identify possible sources of heterogeneity within our sample and to compare between subgroups. Categorical moderator variables were defined *a priori* and included study design (RCT, observational prospective, or observational retrospective), clinical setting (ED, ICU, or mixed settings), and the World Health Organization (WHO) region of the country in which the study was conducted.

We performed sensitivity analysis to assess the impact of each included study on the overall effect size, and ensure no single study had an outsized impact on our findings. Sensitivity analysis was performed using a "one-study removed" random-effects meta-analysis, in which each individual study was systemically removed, and a random-effects meta-analysis was performed on the remainder of the studies. We did not perform any assessment for publication bias, such as a funnel plot: these assessments provide information about potential missing studies that could affect the demonstrated efficacy of interventions, and as our study estimated the prevalence of MAEs, rather than comparing interventions to prevent them, they were not applicable.

All random-effects meta-analysis, sensitivity and moderator analyses and multivariable meta-regressions were performed with the software Comprehensive Meta-Analysis Version 4 (www.meta-analysis. com, Englewood, NJ).

## 3. Results

## 3.1. Study selection

We screened 5,371 abstracts and subsequently reviewed 171 articles and included 44 in our analysis (Fig. 1). Twelve studies met all inclusion criteria but were excluded from analysis due to high likelihood of dual enrollment of patients with another included study (Supp Table 1). Nine included studies were RCTs [27-35]; the rest were observational, 19 prospective [2,5,36-55] and 16 retrospective [7,56-67] (Table 1). Seventeen studies examined intubations in the ED, 23 in the ICU, and 4 in a mix of settings. Half of the included studies were from the Americas.

# 3.2. Study quality

We determined one RCT included in this analysis to have some concern for bias using the Cochrane Risk of Bias tool [31]; we judged the remainder to be of low risk for bias (Table 1). Details regarding study quality assessment by domain are provided in Supplemental Table 2. We judged the majority of the included observational studies to be of high quality using the Newcastle Ottawa Scale, and no studies were judged to be of low quality.

## 3.3. Summary of studies

Our analysis included data from 34,357 intubations, 21,677 of which were performed in the ED, 11,080 in the ICU, and 1,601 elsewhere, most often the medical wards or step-down units. Our patient population was 46% female, with a mean age of 59 (Table 2). Less than half of the included studies reported pre-intubation SBP [2,5,7,30,32,35,48,50,51,55,61-64,66,67], HR [2,7,30,35,51,55,61-64,66,67], IVF [2,5,47,66], or vasopressors [2,5,32-34,38,48,49,51,53,55,56,59,60,63,65-67]. Among studies reporting this data, mean SBP was 131 mmHg and mean HR was 106 bpm; one third of patients received IVF prior to intubation, and 11% vasopressors (Supp Table 3). Preoxygenation techniques were reported in 21 studies [2,5,27,28,30,33-35,38,45,48,49,51,54,55,58,60,62,64,66,67]; low-flow oxygen-including nasal cannula (NC) and non-rebreather mask (NRB)-was the most frequently reported form of preoxygenation (3,565 patients), followed by non-invasive ventilation (NIV)-including bi-level positive airway pressure (BiPAP), continuous positive airway pressure (CPAP), and bag-valve mask (BVM) ventilation-and high-flow nasal cannula (HFNC). All but 5 studies reported reasons for intubation [41-44,54]. Respiratory failure was the most reported impetus for intubation (23%), followed by airway protection (19%; Table 2).




Fig. 1. Flow diagram for study selection<sup>a</sup>.

202

# 3.4. Primary outcome: peri-intubation major adverse events

All 44 studies were included in our primary analysis. Thirty-one percent of patients included in our meta-analysis experienced a peri-intubation MAE (95% CI 25–37%; Fig. 2a). Our analysis reported a Q-statistic, of 5906 with 43 degrees of freedom and p < 0.001. Using a criterion alpha of 0.1, these findings reject the null hypothesis that the true effect size is the same across all included studies.  $I^2$  was 99%, suggesting that no >1% of observed variance was due to sampling error. Tau-squared was 0.820 in logic units, and tau was 0.906 in logic units; from this calculation, we estimated that the prediction interval is 6.5–73.6%.

MAEs were less common (p = 0.001) among studies examining ED intubations (17%, 95% Cl 12–24%), when compared to those examining ICU intubations (41%, 95% Cl 33–49%) and intubations across multiple settings (41%, 24–61%; Table 3a). There was no significant difference in MAE rates when studies were compared across World Health Organization (WHO) regions, or by study type.

Our meta-regression (Table 3b) suggested a direct proportional correlation between rates of peri-intubation MAE in studies with the percentage of patients undergoing intubation for hemodynamic instability (Correlation Coefficient [Corr. Coeff.] 1.9, 95% CI 0.2–3.5,

#### Table 1

Characteristics of included studies.

p = 0.03). Percentage of patients undergoing induction with propofol (Corr. Coeff. 3.4, 95% CI 0.2–6.7, p = 0.04) or with succinylcholine (Corr. Coeff. 4.5, 95% CI 1.9–7.0, p = 0.01) were positively correlated with prevalence of MAE, while percentage of patients intubated for airway protection (Corr. Coeff. –1.5, 95% CI –2.7 – –0.3, p = 0.02) was negatively correlated with the prevalence of peri-intubation MAE.

Our sensitivity analysis using random effects meta-analysis with one-study removed identified a consistent MAE rate of 30.5% (95% CI 22–38%), (Fig. 2b). This suggests that no single study disproportionately impacted the meta-analysis' overall effect size.

# 3.5. Secondary outcomes: hypoxia, cardiac arrest, and cardiovascular collapse

Our analysis of the prevalence of peri-intubation hypoxia was based on 28 studies. Hypoxia was identified in 15% of patients following intubation (95% CI 11.5–19%; Fig. 3a). This analysis was associated with a Q statistic of 1202 with 27 degrees of freedom and p < 0.001, rejecting the null hypothesis that the true effect size is the same across all included studies.  $l^2$  was 98%. Tau-squared was 0.578 in logic units, and tau was 0.760 in logic units. We estimated that the prediction interval is 3.4–46.1%. Sensitivity analysis did not identify any individual study

| Study (Year, Author)                    | Country       | WHO Region | Setting | Study Type         | Quality Rating |
|---|---------------|------------|---------|--------------------|----------------|
| 1996 Khan [36]                          | Pakistan      | EMR        | ICU     | Obs. Prospective   | 8              |
| 2006 Baillard [27]                      | France        | EUR        | ICU     | RCT                | Low Concern    |
| 2006 Simpson [37]                       | Scotland      | EUR        | ED      | Obs. Prospective   | 6              |
| 2008 Griesdale [38]                     | Canada        | AMR        | MIxed   | Obs. Prospective   | 8              |
| 2011 Mayo [39]                          | USA           | AMR        | ICU     | Obs. Prospective   | 4              |
| 2012 Green [56]                         | Canada        | AMR        | ED      | Obs. Retrospective | 9              |
| 2013 Heffner [7]                        | USA           | AMR        | ED      | Obs. Retrospective | 8              |
| 2013 Imamura [40]                       | Japan         | WPR        | ED      | Obs. Prospective   | 9              |
| 2013 Sakles [57]                        | USA           | AMR        | ED      | Obs. Retrospective | 7              |
| 2014 Roux [41]                          | France        | EUR        | ED      | Obs. Prospective   | 5              |
| 2015 Mosier (a) [42]                    | USA           | AMR        | ICU     | Obs. Prospective   | 5              |
| 2015 Mosier (b) [58]                    | USA           | AMR        | ICU     | Obs. Retrospective | 8              |
| 2015 Smith [43]                         | USA           | AMR        | ED      | Obs. Prospective   | 8              |
| 2015 Trivedi [59]                       | USA           | AMR        | ICU     | Obs. Retrospective | 8              |
| 2016 Bodily [44]                        | USA           | AMR        | ED      | Obs. Prospective   | 5              |
| 2016 Cham [60]                          | Hong Kong     | WPR        | Mixed   | Obs. Retrospective | 5              |
| 2016 [aber [28]                         | France        | EUR        | ICU     | RCT                | Low Concern    |
| 2016 Janz [29]                          | USA           | AMR        | ICU     | RCT                | Low Concern    |
| 2016 Ono [61]                           | Japan         | WPR        | ED      | Obs. Retrospective | 9              |
| 2016 Sakles [45]                        | USA           | AMR        | ED      | Obs. Prospective   | 8              |
| 2017 April [46]                         | USA           | AMR        | ED      | Obs. Prospective   | 8              |
| 2017 Smischney [62]                     | USA           | AMR        | ICU     | Obs. Retrospective | 7              |
| 2017 Van Berkel [63]                    | USA           | AMR        | ICU     | Obs. Retrospective | 9              |
| 2017 Vall Berker [05]<br>2018 Baek [64] | Korea         | WPR        | MIxed   | Obs. Retrospective | 8              |
|   | USA           |            | ICU     | 1                  | o<br>4         |
| 2018 Corl [47]                          |               | AMR        |         | Obs. Prospective   | 4<br>7         |
| 2018 De Jong [48]                       | France        | EUR        | ICU     | Obs. Prospective   |                |
| 2018 Driver [30]                        | USA           | AMR        | ED      | RCT                | Low Concern    |
| 2018 Grensemann [31]                    | Germany       | EUR        | ICU     | RCT                | Some Concer    |
| 2018 Janz [32]                          | USA           | AMR        | Mixed   | RCT                | Low Concern    |
| 2019 Casey [33]                         | USA           | AMR        | ICU     | RCT                | Low Concern    |
| 2019 Frat [34]                          | France        | EUR        | ICU     | RCT                | Low Concern    |
| 2019 Smischney [55]                     | USA           | AMR        | ICU     | Obs. Prospective   | 8              |
| 2020 Amalric [49]                       | France        | EUR        | ICU     | Obs. Prospective   | 5              |
| 2020 Chanthawatthanarak [50]            | Thailand      | SEAR       | ED      | Obs. Prospective   | 8              |
| 2020 de Alencar [51]                    | Brazil        | AMR        | ED      | Obs. Prospective   | 9              |
| 2020 Mohr [65]                          | International | Other      | ED      | Obs. Retrospective | 9              |
| 2020 Nong [35]                          | China         | WPR        | ICU     | RCT                | Low Concern    |
| 2020 Smischney [5]                      | USA           | AMR        | ICU     | Obs. Prospective   | 8              |
| 2021 Mbanjumucyo [52]                   | Rwanda        | AFR        | ED      | Obs. Prospective   | 8              |
| 2021 Russotto [2]                       | International | Other      | Mixed   | Obs. Prospective   | 5              |
| 2021 Walimanna Gamage [53]              | Sri Lanka     | SEAR       | ICU     | Obs. Prospective   | 5              |
| 2021 Zhang [54]                         | China         | WPR        | ICU     | Obs. Prospective   | 8              |
| 2022 Ergün [66]                         | Turkey        | EUR        | ICU     | Obs. Retrospective | 7              |
| 2022 Yang [67]                          | Taiwan        | WPR        | ED      | Obs. Retrospective | 7              |

Abbreviations: USA, United States of America; WHO, World Health Organization; EMR, Eastern Mediterranean Region; AMR, Region of the Americas; EUR, European Region; WPR, Western Pacific Region; SEAR, South-East Asian Region; AFR, African Region; ICU, intensive care unit; ED, Emergency Department; Obs., Observational; RCT, Randomized Control Trial. <sup>a</sup> The quality of observational studies was assessed using the Newcastle Ottawa Scale (1–9). The quality of randomized control trials was assessed using the Cochrane Risk of Bias 2 tool.

203

| Study                                      | Demographics   |                         |                      |                  | Reason for Intubation    | tubation                   |                         |                         |                          | Complications               |                  |                         |                         |
|--|----------------|-------------------------|----------------------|------------------|--------------------------|----------------------------|-------------------------|-------------------------|--------------------------|-----------------------------|------------------|-------------------------|-------------------------|
| Year, Author                               | Total Patients | Female<br>N (%)         | Age<br>Mean (SD)     | BMI<br>Mean (SD) | Resp<br>Failure<br>N (%) | Airway Protection<br>N (%) | CV Instability<br>N (%) | Cardiac Arrest<br>N (%) | Other<br>N (%)           | CV Instability<br>N (%)     | Hypoxia<br>N (%) | Cardiac Arrest<br>N (%) | Any MAE<br>N (%)        |
| 1996 Khan [36]                             | 126            | NR                      | 47 (18)              | NR               | 0 (0%)                   | 0 (0%)                     | 0 (0%)                  | 0 (0%)                  | 126 (100%)               | 6 (5%)                      | NR               | NR                      | 6 (5%)                  |
| 2006 Baillard [27]                         | 53             | 17 (32%)                | NR                   | NR               | 45 (85%)                 | 0 (0%)                     | 0 (0%)                  | 0 (0%)                  | 4 (8%)                   | NR                          | 14 (26%)         | NR                      | 14 (26%)                |
| 2006 Simpson [37]                          | 180            | NR                      | NR                   | NR               | 0 (0%)                   | 0 (0%)                     | 0 (0%)                  | 0 (0%)                  | 180 (100%)               | 6 (3%)                      | 15(8%)           | 2 (1%)                  | 23 (13%)                |
| 2008 Griesdale [38]                        | 136            | 51 (38%)                | 58 (18)              | 26(7)            | 89 (65%)                 | 25 (18%)                   | 11 (8%)                 | 0 (0%)                  | 11 (8%)                  | 13 (10%)                    | 26 (19%)         | 61 (45%)                | 100 (74%)               |
| 2011 Mayo [39]                             | 128            | NR<br>85 (2000)         | NR<br>En (21)        | NR               | 34 (27%)                 | 29 (23%)                   | 0 (0%)                  | 0 (0%)                  | 65 (51%)                 | 20 (16%)                    | NR               | 1 (1%)                  | 21 (16%)                |
| 2012 Green [56]                            | 218            | (%62) C8                | (17) /5              | NK               | (%17) 64                 | 14 (b%)<br>201 (72%)       | 0 (0%)                  | 0 (0%)                  | 135 (62%)                | 90 (44%)                    | NK               | NK<br>17 ( 180)         | 90 (44%)                |
| 2013 Hermer [7]<br>2013 Imamura [40]       | 410<br>3178    | 147 (30%)<br>1253 (39%) | 49 (19)<br>65 (19)   | NR<br>NR         | 80 (20%)<br>570 (18%)    | 294 (72%)<br>971 (31%)     | U (U%)<br>271 (9%)      | 0 (0%)<br>1174 (37%)    | 30 (9%)<br>192 (6%)      | NK<br>46 (1%)               | NK<br>5 (0%)     | 1 / (4%)<br>4 (0%)      | 17 (4%)<br>55 (2%)      |
| 2013 Sakles [57]                           | 1828           | 635 (35%)               | NR                   | NR               | 312 (17%)                | 1143 (63%)                 | 26 (1%)                 | 200 (11%)               | 147 (8%)                 | 5 (0%)                      | 309 (17%)        | 3 (0%)                  | 317 (17%)               |
| 2014 Roux [41]                             | 1007           | NR                      | NR                   | NR               | NR                       | NR                         | NR                      | NR                      | NR                       | NŘ                          | 87 (9%)          | NŘ                      | 87 (9%)                 |
| 2015 Mosier (a) [42]                       | 861            | 376 (44%)               | NR                   | NR               | NR                       | NR                         | NR                      | NR                      | NR                       | 71 (8%)                     | 189 (22%)        | 4(0%)                   | 264 (31%)               |
| 2015 Mosier (b) [58]                       | 235            | 96 (41%)                | NR                   | NR               | 183 (78%)                | 37 (16%)                   | 12 (5%)                 | 0 (0%)                  | 3 (1%)                   | 70 (30%)                    | 66 (28%)         | NR                      | 136 (58%)               |
| 2015 Smith [43]                            | 141            | NR                      | NR                   | NR               | NR                       | NR                         | NR                      | NR                      | NR                       | 2 (1%)                      | 7 (5%)           | 0 (0%)                  | 0 (6%) 9                |
| 2015 Trivedi [59]                          | 140<br>150     | 63 (45%)                | 62 (15)              | NR               | 108 (77%)                | 91 (65%)                   | 0 (0%)                  | 0 (0%)                  | 0 (0%)                   | 55 (39%)                    | NR<br>FO (2000)  | NR                      | 55 (39%)                |
| 2016 Bodily [44]                           | 166            | (%)                     | NK                   | NK               | NK                       | NK                         | NK                      | NK                      | NK                       | NK                          | 59 (36%)         | NK                      | 59 (36%)<br>26 (26%)    |
| 2016 Cham [60]                             | 525<br>01      | 108 (33%)<br>11 (77%)   | 67 (10)              | NK<br>24 (2)     | 186 (%/c) 081<br>(%) 0   | 42 (13%)<br>0 (0%)         | 24 (7%)<br>0 (0%)       | 33 (10%)<br>0 (0%)      | 40 (12%)<br>40 (100%)    | 69 (21%)<br>12 (77%)        | NK<br>6 (13%)    | 4 (1%)<br>0 (0%)        | /3 (22%)<br>10 (20%)    |
| 2010 Jauet [20]<br>2016 Janz [29]          | 150<br>150     | 11 (22%)<br>59 (39%)    | NR                   | NR (U)           | 0 (0%)<br>85 (57%)       | 39 (26%)                   | 0 (0%)                  | 0 (0%)                  | 45 (100%)<br>26 (18%)    | 15 (10%)                    | 30(20%)          | 0 (0%)<br>2 (1%)        | 47 (31%)                |
| 2016 Ono [61]                              | 123            | 38 (31%)                | 56 (10)              | NR               | 76 (62%)                 | 0 (0%)                     | 0 (0%)                  | 0 (0%)                  | 47 (38%)                 | 7 (6%)                      | NR               | 5 (4%)                  | 12 (10%)                |
| 2016 Sakles [45]                           | 127            | 37 (29%)                | NR                   | NR               | 1 (1%)                   | 117 (92%)                  | 0 (0%)                  | 0 (0%)                  | 9 (7%)                   | 13 (10%)                    | NR               | NR                      | 13 (10%)                |
| 2017 April [46]                            | 259            | NR                      | NR                   | NR               | 12 (5%)                  | 31 (12%)                   | 10 (4%)                 | 14(5%)                  | 8 (3%)                   | 13 (5%)                     | 36 (14%)         | 10 (16%)                | 59 (23%)                |
| 2017 Smischney [62]                        | 420            | 176(42%)                | NR                   | NR               | 282 (67%)                | 173 (41%)                  | 166(40%)                | 18(4%)                  | 103 (25%)                | NR                          | 74 (18%)         | NR                      | 74 (18%)                |
| 2017 Van Berkel [63]                       | 384            | 184(48%)                | NR                   | NR               | 340 (89%)                | 35 (9%)                    | 5(1%)                   | 0 (0%)                  | 4(1%)                    | 244 (64%)                   | NR               | NR                      | 244 (64%)               |
| 2018 Baek [64]                             | 958<br>257     | 337 (35%)               | 63 (6)               | NR               | 658 (69%)                | 138 (14%)                  | 128 (13%)               | 0(0%)                   | 4 (0%)<br>5 (0%)         | 181 (19%)                   | 24 (3%)          | NR<br>2 (100)           | 205 (21%)               |
| 2018 Corl [47]                             | 275            | 143 (52%)<br>GEE (25%)  | NK                   | NK               | 0 (0%)                   | 44 (16%)                   | 199 (72%)               | 16(6%)                  | 5 (2%)<br>1947 (100%)    | 33 (12%)<br>1076 (FFW)      | NK               | 3 (1%)                  | 36 (13%)<br>1075 (58%)  |
| 2018 De Jong [48]<br>2018 Driver [20]      | 184/<br>757    | (%CE) CCO<br>(%OE) OEC  | NK                   | NK               | U (U%)<br>20 (5%)        | U (U%)<br>ADE (EA%)        | U (U%)<br>48 (6%)       | U (U%)<br>55 (7%)       | 1847 (100%)<br>708 (04%) | 1026 (%cc) 0201<br>07 (12%) | NP               | 49 (3%)<br>55 (7%)      | (%8c) C/0I              |
| 2018 Grensemann [31]                       | 53             | 24 (45%)                | NR                   | NR               | (%C) CC<br>(%D) 0        | 400 (J4%)<br>0 (0%)        | 48 (0%)<br>0 (0%)       | 0 (0%)<br>0 (0%)        | 53 (100%)                | 9 (17%)                     | 9 (17%)          | NR                      | 132 (20%)               |
| 2018 Janz [32]                             | 262            | 97,937%)                | NR                   | NR               | 224 (85%)                | 99 (38%)                   | 28 (11%)                | 0 (0%)                  | 34 (13%)                 | 58 (22%)                    | 60 (23%)         | 7 (3%)                  | 125 (48%)               |
| 2019 Casey [33]                            | 401            | 175 (44%)               | NR                   | NR               | 327 (82%)                | 150 (37%)                  | 0 (0%)                  | 0 (0%)                  | 34 (8%)                  | 25 (6%)                     | 85 (21%)         | 6 (1%)                  | 116 (29%)               |
| 2019 Frat [34]                             | 313            | 101 (32%)               | NR                   | NR               | 186 (59%)                | 13 (4%)                    | 66 (21%)                | 0 (0%)                  | 12 (4%)                  | 156(50%)                    | 80 (26%)         | 6 (2%)                  | 242 (77%)               |
| 2019 Smischney [55]                        | 269            | 124 (46%)               | NR                   | NR               | 169 (63%)                | 109 (41%)                  | 0 (0%)                  | 6 (2%)                  | 42 (16%)                 | 141 (52%)                   | NR               | NR                      | 141 (52%)               |
| 2020 Amalric [49]                          | 202            | 76 (38%)                | 66(5)                | 26 (2)           | 122 (60%)                | 0 (0%)                     | 24 (12%)                | 4 (2%)                  | 44 (22%)                 | 35 (17%)                    | NR               | 2 (1%)                  | 37 (18%)                |
| 2020 Chanthawatthanarak [50]               | 267            | 100 (37%)<br>51 (46%)   | 67 (15)<br>MD        | NR               | 173 (65%)                | 51 (19%)<br>2 (7%)         | 29 (11%)<br>110 (68%)   | 0 (0%)                  | 14 (5%)<br>0 (0%)        | 16 (6%)<br>106 (05%)        | 2 (1%)           | 4 (1%)<br>2 (1%)        | 22 (8%)<br>108 (06%)    |
| 2020 ער אופווכאו (21)<br>2020 אוסאיי (155) | 112<br>1777    | 31 (40%)<br>8450 (66%)  | NR                   | NR               | 0 (0%)                   | 2 (2%)<br>0 (0%)           | 110 (90%)<br>531 (4%)   | 0 (0%)                  | U (U%)<br>12 191 (96%)   | 100 (33%)<br>2051 (16%)     | DEG (8%)         | 2 (1%)<br>NR            | 100 (90%)<br>3017 (24%) |
| 2020 Nong [35]                             | 12,722         | 31 (29%)                | NR                   | NR               | 102 (96%)                | 0 (0%)                     | 0(0%)                   | 0 (0%)                  | 4 (4%)                   | 37 (35%)                    | 24 (23%)         | NR                      | 61(58%)                 |
| 2020 Smischney [5]                         | 1033           | 431 (42%)               | 62 (15)              | 30 (9)           | 751 (73%)                | 888 (86%)                  | 189 (18%)               | 41 (4%)                 | 187 (18%)                | 189 (18%)                   | 216 (21%)        | NR                      | 405 (39%)               |
| 2021 Mbanjumucyo [52]                      | 198            | 52 (26%)                | 36 (8)               | NR               | NR                       | 146 (74%)                  | NR                      | 13 (7%)                 | 4 (2%)                   | 20 (10%)                    | 45 (23%)         | 7 (4%)                  | 65 (33%)                |
| 2021 Russotto [2]                          | 2964           | 1107 (37%)              | 62 (7)               | 26 (2)           | 1685 (57%)               | 902 (30%)                  | 277 (9%)                | NR                      | 96 (3%)                  | 1172(40%)                   | 272 (9%)         | 93 (3%)                 | 1537 (52%)              |
| 2021 Walimanna Gamage [53]                 | 150            | 63 (42%)                | NR                   | NR               | 0 (0%)                   | 0 (%)                      | 0 (%)                   | 0 (0%)                  | 129 (86%)                | 69(46%)                     | 75 (50%)         | 4 (3%)                  | 148 (98%)               |
| 2021 Zhang [54]                            | 315            | 103 (33%)               | 32 (11)<br>32 (1)    | 37 (11)          | NR<br>111 (1000()        | NR<br>6 (200)              | NR<br>2 (200)           | NR<br>S (SSV)           | NR<br>6 (800)            | 154 (49%)                   | 79 (25%)         | 10 (7%)                 | 243 (77%)               |
| 2022 Ergun [66]                            | 141<br>368     | 39 (28%)<br>177 (75%)   | (c) <i>E</i> /<br>un | 26 (1)<br>MD     | 141 (100%)<br>211 (57%)  | 0 (0%)<br>00 (34%)         | 0 (0%)<br>MD            | 0 (0%)                  | 0 (0%)<br>68 (78%)       | NK                          | 141 (100%)<br>MB | 0 (0%)<br>01 (75%)      | 141 (100%)              |
| 2022 זמווצ (טין                            | 000            | (arr) 171               | VIN                  | NN               | (arr) 117                | 00 (م <del>1</del> 2)      | INI                     | n (wn)                  | 100 (2010)               | VINI                        | VINI             | 74 (40/07               | 101C7) 7C               |

Descargado para Lucia Angulo (lu.maru26@gmail.com) en National Library of Health and Social Security de ClinicalKey.es por Elsevier en septiembre 18, 2023. Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2023. Elsevier Inc. Todos los derechos reservados.

204

\_

1.00

# Study name

а

# Event rate and 95% CI

|  | Event<br>rate | Lower<br>limit | Up per<br>limit |         |      |            |
|--|---------------|----------------|-----------------|---------|------|------------|
| 1996 Khan                                | 0.048         | 0.022          | 0.102           |         | 1    | I.         |
| 2006 Baillard                            | 0.264         | 0.163          | 0.398           | _       |      |            |
| 2006 Simp son                            | 0.128         | 0.086          | 0.185           | -       |      |            |
| 2008 Griesdale                           | 0.735         | 0.655          | 0.803           |         |      | -          |
| 2011 Mayo                                | 0.164         | 0.109          | 0.239           | -       |      |            |
| 2012 Green                               | 0.440         | 0.376          | 0.507           |         |      | н          |
| 2013 Heffner                             | 0.041         | 0.026          | 0.066           |         |      |            |
| 2013 Imamura                             | 0.017         | 0.013          | 0.022           |         |      |            |
| 2013 Sakles                              | 0.173         | 0.157          | 0.191           |         |      |            |
| 2014 Roux                                | 0.086         | 0.071          | 0.105           |         |      |            |
| 2015 Mosier (a)                          | 0.307         | 0.277          | 0.338           |         | -    |            |
| 2015 Mosier (b)                          | 0.579         | 0.515          | 0.640           |         | _    | _          |
| 2015 Smith                               | 0.064         | 0.034          | 0.118           | -       |      | <b>–</b>   |
| 2015 Trivedi                             | 0.393         | 0.316          | 0.476           |         | -    |            |
| 2016 Bodily                              | 0.355         | 0.286          | 0.431           |         |      |            |
| 2016 Cham                                | 0.225         | 0.183          | 0.273           | -       | -    |            |
| 2016 Jaber                               | 0.388         | 0.263          | 0.529           |         |      | 1          |
| 2016 Janz                                | 0.313         | 0.244          | 0.392           |         |      |            |
| 2016 Ono                                 | 0.098         | 0.056          | 0.164           |         | -    |            |
| 2016 Sakles                              | 0.102         | 0.060          | 0.168           |         |      |            |
| 2017 April                               | 0.228         | 0.181          | 0.283           |         |      |            |
| 017 Smischney                            | 0.176         | 0.143          | 0.216           |         |      |            |
| 017 van Berkel                           | 0.635         | 0.586          | 0.682           | -       |      | 1.00       |
| 018 Baek                                 | 0.214         | 0.189          | 0.241           |         |      | -          |
| 018 Corl                                 | 0.131         | 0.096          | 0.176           | 1 - 1   |      |            |
| 018 De Jong                              | 0.582         | 0.559          | 0.604           |         |      |            |
| 018 Driver                               | 0.201         | 0.174          | 0.231           |         |      | -          |
| 018 Grensemann                           | 0.340         | 0.226          | 0.476           |         | -    |            |
| 018 Janz                                 | 0.477         | 0.417          | 0.538           |         | 1.0  |            |
| 019 Casey                                | 0.289         | 0.247          | 0.336           |         |      |            |
| 019 Frat                                 | 0.233         | 0.723          | 0.816           |         | -    |            |
| 019 Smischney                            | 0.524         | 0.464          | 0.583           |         |      |            |
| 020 Amalric                              | 0.524         | 0.404          | 0.243           | _       |      |            |
| 020 Amairic<br>020 Chanthawatthanarak    | 0.183         | 0.055          | 0.243           |         | 1    |            |
| 020 Chanthawatthanarak<br>020 de Alencar |               | 0.055          | 0.122           | -       |      |            |
| 020 de Alencar<br>020 Mohr               | 0.964         | 0.909          | 0.987           | _       | 1    |            |
|  |               |                | 0.245           |         | T    |            |
| 020 Nong                                 | 0.575         | 0.480          |                 |         |      | T <b>-</b> |
| 020 Smischney                            | 0.392         | 0.363          | 0.422           |         | -    |            |
| 021 Mbanjumucyo                          | 0.328         | 0.266          | 0.397           |         |      | -          |
| 021 Russotto                             | 0.519         | 0.501          | 0.537           |         |      |            |
| 021 WalimannaGamange                     | 0.987         | 0.948          | 0.997           |         |      |            |
| 2021 Zhang                               | 0.771         | 0.722          | 0.814           |         |      |            |
| 022 Ergün                                | 0.376         | 0.300          | 0.459           |         | ⊥-■- |            |
| 022 Yang                                 | 0.250         | 0.208          | 0.297           | 1       |      |            |
| Pooled                                   | 0.305         | 0.250          | 0.366           |         | •    |            |
| Prediction Interval                      | 0.305         | 0.065          | 0.736           | H       |      | 1          |
| Test of heteroger                        |               |                |                 | 0.00 0. | 25   | 0.50       |
| Q-value                                  | D(f)          | Р              | 12              |         |      |            |
| 3905                                     | 43            | 0.001          | >90%            |         |      |            |

Fig. 2. a. Prevalence of peri-intubation major adverse events in patients undergoing intubation outside of the post-anesthesia care unit or operating room. b. Sensitivity analysis for prevalence of peri-intubation major adverse events, performed using random-effects meta-analysis with one-study-removed.

# Name of Removed Study

b

| Event rate (95%CI) |
|--------------------|
| with study removed |

| Removed Study                          |       |                |                | wit   | th study removed |
|--|-------|----------------|----------------|-------|------------------|
|  | Point | Lower<br>limit | Upper<br>limit |       |                  |
| 1996 Khan                              | 0.314 | 0.258          | 0.377          | 1 1-  | - T T            |
| 2006 Baillard                          | 0.306 | 0.250          | 0.368          |       | -                |
| 2006 Simpson                           | 0.310 | 0.254          | 0.373          |       |                  |
| 2008 Griesdale                         | 0.296 | 0.242          | 0.356          |       |                  |
| 2011 Mayo                              | 0.309 | 0.253          | 0.371          |       |                  |
| 2012 Green                             | 0.302 | 0.247          | 0.364          |       |                  |
| 2013 Heffner                           | 0.316 | 0.260          | 0.378          |       |                  |
| 2013 Imamura                           | 0.321 | 0.267          | 0.380          |       |                  |
| 2013 Sakles                            | 0.309 | 0.252          | 0.372          |       |                  |
| 2014 Roux                              | 0.313 | 0.257          | 0.374          |       | -                |
| 2015 Mosier (a)                        | 0.305 | 0.248          | 0.368          |       |                  |
| 2015 Mosier (b)                        | 0.299 |                | 0.360          | - I - |                  |
| 2015 Smith                             | 0.313 | 0.257          | 0.376          |       |                  |
| 2015 Trivedi                           | 0.303 | 0.247          | 0.365          |       |                  |
| 2016 Bodily                            | 0.304 | 0.248          | 0.366          |       |                  |
| 2016 Cham                              | 0.307 | 0.251          | 0.370          |       |                  |
| 2016 Jaber                             | 0.303 | 0.248          | 0.365          |       |                  |
| 2016 Janz                              | 0.305 | 0.249          | 0.367          |       |                  |
| 2016 Ono                               | 0.311 | 0.255          | 0.374          |       | - I I            |
| 2016 Sakles                            | 0.311 | 0.255          | 0.374          |       |                  |
| 2017 April                             | 0.307 | 0.251          | 0.369          |       |                  |
| 2017 Smischney                         | 0.309 |                | 0.371          |       |                  |
| 2017 van Berkel                        | 0.298 | 0.243          | 0.358          |       |                  |
| 2018 Baek                              | 0.308 | 0.251          | 0.371          |       |                  |
| 2018 Corl                              | 0.310 | 0.254          | 0.373          |       |                  |
| 2018 De Jong                           | 0.299 | 0.245          | 0.358          |       |                  |
| 2018 Driver                            | 0.308 | 0.251          | 0.371          |       |                  |
| 2018 Grensemann                        | 0.304 | 0.249          | 0.366          |       |                  |
| 2018 Janz                              | 0.301 | 0.246          | 0.363          |       |                  |
| 2019 Casey                             | 0.305 | 0.249          | 0.368          |       |                  |
| 2019 Frat                              | 0.294 | 0.241          | 0.354          |       |                  |
| 2019 Smischney                         | 0.300 | 0.245          | 0.362          |       |                  |
| 2020 Amalric                           | 0.308 | 0.252          | 0.371          |       |                  |
| 2020 Chanthawatthanarak                | 0.313 | 0.256          | 0.375          |       | _                |
| 2020 de Alencar                        | 0.289 | 0.236          | 0.349          |       |                  |
| 2020 Mohr                              | 0.308 | 0.246          | 0.378          |       | _                |
| 2020 Nong                              | 0.299 |                | 0.361          |       | _                |
| 2020 Smischney                         | 0.303 | 0.246          | 0.367          |       |                  |
| 2020 Silliscinicy<br>2021 Mbanjumucy o | 0.303 | 0.240          | 0.367          |       |                  |
| 2021 Russotto                          | 0.300 |                | 0.362          |       |                  |
| 2021 WalimannaGamange                  | 0.289 |                | 0.348          |       |                  |
| 2021 WannamaGamange<br>2021 Zhang      | 0.294 | 0.230          | 0.354          |       |                  |
| 2021 Ergün                             | 0.303 | 0.241          | 0.365          |       |                  |
| 2022 Yang                              | 0.306 | 0.248          | 0.369          |       |                  |
| Pooled                                 | 0.305 | 0.250          | 0.366          |       |                  |
| Prediction Interval                    | 0.305 |                | 0.300          |       |                  |
| a concerna mila val                    | 0.505 | 0.005          | 0.750          | 1 ' 1 | 1 1              |

Fig. 2 (continued).

. . . . . . . . .

#### Table 3

Moderator analysis and meta-regression for primary outcome of any peri-intubation MAE.

| Moderator Variab | oles              | Meta-analys | is      |           | Heterogene | eity |       |       | Between group comparisor |
|------------------|-------------------|-------------|---------|-----------|------------|------|-------|-------|--------------------------|
|                  |                   | # Studies   | Outcome | 95% CI    | Q-value    | D(f) | Р     | $I^2$ | Р                        |
| Study design     | RCT               | 9           | 0.4     | 0.27-0.56 | 304        | 8    | 0.001 | >90   | 0.21                     |
|                  | Obs prospective   | 19          | 0.26    | 0.19-0.34 | 2086       | 18   | 0.001 | >90   |                          |
|                  | Obs retrospective | 16          | 0.32    | 0.23-0.42 | 674        | 15   | 0.001 | >90   |                          |
| Study settings   | ED                | 17          | 0.17    | 0.12-0.24 | 853        | 16   | 0.001 | >90   | 0.001                    |
|                  | ICU               | 23          | 0.41    | 0.33-0.49 | 948        | 22   | 0.001 | >90   |                          |
|                  | Mixed             | 4           | 0.41    | 0.24-0.61 | 351        | 3    | 0.001 | >90   |                          |
| WHO regions      | AMR               | 22          | 0.32    | 0.23-0.42 | 954        | 21   | 0.001 | >90   | 0.42                     |
|                  | EUR               | 9           | 0.32    | 0.19-0.48 | 729        | 8    | 0.001 | >90   |                          |
|                  | SEAR              | 2           | 0.59    | 0.23-0.88 | 81         | 2    | 0.001 | >90   |                          |
|                  | WPR               | 7           | 0.23    | 0.12-0.40 | 832        | 6    | 0.001 | >90   |                          |
|                  | Multi-national    | 2           | 0.37    | 0.12-0.71 | 864        | 1    | 0.001 | >90   |                          |
|                  | Other             | 2           | 0.14    | 0.04-0.43 | 26         | 1    | 0.001 | >90   |                          |

#### B. Meta-Regression

|                              | Variables                       | # Studies | Corr. Coeff. | 95% CI         | Р    |
|------------------------------|---------------------------------|-----------|--------------|----------------|------|
| Demographics                 | Age (mean)                      | 12        | 0.02         | -0.06-0.10     | 0.86 |
|                              | Female (%)                      |           | -4.20        | -12.1-3.40     | 0.28 |
|                              | BMI (kg/m <sup>2,</sup> mean)   |           | 0.02         | -0.14-0.18     | 0.82 |
| Vital signs                  | Pre-intubation SBP (mmHg, mean) | 13        | -0.04        | -0.10 to -0.01 | 0.14 |
|                              | Pre-intubation HR (bpm, mean)   |           | -0.01        | -0.09 - 0.08   | 0.79 |
| Reasons for intubation       | Respiratory failure (%)         | 37        | 0.90         | -0.01 - 1.80   | 0.05 |
|                              | Airway protection (%)           |           | -1.50        | -2.70 - 0.28   | 0.02 |
|                              | CV instability (%)              |           | 1.90         | 0.20-3.50      | 0.03 |
| Pre-Intubation Interventions | Vasopressors/Inotropes (%)      | 7         | -0.70        | -3.30-1.80     | 0.56 |
|                              | Preoxygenation with NIV (%)     |           | 3.10         | -2.40-8.50     | 0.27 |
|                              | Preoxygenation with HFNC (%)    |           | 1.90         | -2.70-6.60     | 0.4  |
| Induction Medications        | Propofol (%)                    | 11        | 3.40         | 0.19-6.71      | 0.04 |
|                              | Etomidate (%)                   |           | 1.30         | -0.11-2.78     | 0.07 |
|                              | Midazolam (%)                   |           | -0.33        | -2.40 - 1.74   | 0.76 |
| NMB                          | Succinylcholine (%)             | 17        | 4.50         | 1.90-7.02      | 0.01 |
|                              | Rocuronium (%)                  |           | 1.80         | -0.45 - 4.11   | 0.12 |

Abbreviations: RCT, randomized control trial; ED, emergency department; ICU, intensive care unit; WHO, World Health Organization; AMR, Region of the Americas; EUR, European Region; SEAR, South-East Asian Region; WPR, Western Pacific Region; BMI, body mass index; CV, cardiovascular; NIV, non-invasive ventilation; HFNC, high-flow nasal annula.

that disproportionately impacted the overall effect size of hypoxia prevalence (Fig. 3b).

Rates of hypoxia varied significantly (p = 0.001) by location of intubation, ranging from 8% in studies examining ED intubations (95% CI 6–12%) and those in mixed settings (95% CI 4–16%) to 24% (95% CI 18–31%) in the ICU (Table 4a). We also observed significant variation in rates of hypoxia based on WHO region; studies completed in the Western Pacific Region had the lowest rates of hypoxia (8%, 95% CI 4–17%), while those completed in the Americas had the highest (20%, 95% CI 15–24%). Hypoxia was most common in RCTs (21%, 95% CI 13–30%), and least commonly in observational prospective studies (8%, 95% CI 5–13%).

Multivariable meta-regression (Table 4b) indicated that age, and higher percentages of female patients, patients intubated for respiratory failure or receiving propofol or either succinylcholine or rocuronium were positively correlated with higher prevalence of hypoxia, while higher mean BMI and higher percentages of patients receiving midazolam were negatively correlated with higher prevalence of hypoxia.

Our analysis of peri-intubation cardiac arrest was based on 28 studies. Peri-intubation cardiac arrest occurred in 2% (95% CI 1–3.5%) of patients included in our meta-analysis (Fig. 4a). This analysis was associated with a Q statistic of 716 with 27 degrees of freedom and p = 0.001, and  $l^2$  was 96%. Tau-squared was 2.006, and tau was 1.416 in logic units. We estimated that the prediction interval is 0.1–28.8%. Sensitivity analysis also did not identify any individual study that overwhelmingly affected the overall effect size for prevalence of cardiac arrest (Fig. 4b). There was no significant difference in rates of cardiac arrest based on studies' WHO region, location of intubation (ED v ICU v mixed), or study type (Table 4a). Multivariable meta-regression (Table 4b) suggested that a higher mean HR prior to intubation (Corr. Coeff. 0.13, 95% Cl 0.01–0.25, p = 0.03) was associated with a higher prevalence of peri-intubation cardiac arrest, while a greater percentage of patients receiving etomidate during induction (Corr. Coeff. -2.7, 95% Cl -5.2--0.1, p = 0.04) were associated with lower prevalence of peri-intubation cardiac arrest.

Peri-intubation cardiovascular collapse was reported by 37 included studies and occurred in 18% (95% Cl 13–23%) of patients included in our analysis (Supp Fig. 1a). This analysis was associated with a Q statistic, of 3453 with 36 degrees of freedom and p = 0.001, and  $l^2$  was >90%. We estimated that the prediction interval is 3–63%. Sensitivity analysis did not identify any individual study that overwhelmingly affected the overall effect size for prevalence of cardiac arrest (Supp Fig. 1b). Studies reporting ED intubations had significantly lower rates of cardiovascular collapse than those reporting intubations in the ICU or mixed settings (Table 4a); there was no significant difference in rates of cardiovascular collapse based on studies' WHO region or study type.

Multivariable meta-regression (Table 4b) suggested that intubation for pre-existing cardiovascular instability (Corr. Coeff. 2.90, 95% CI 0.91–4.80, p = 0.004), and use of propofol (Corr. Coeff. 7.50, 95% CI 3.20–11.7, p = 0.001) or succinylcholine (Corr. Coeff. 5.60, 95% CI 1.90–9.30, p = 0.003) during induction were associated with a higher prevalence of peri-intubation cardiovascular collapse; older age (Corr. Coeff. 0.08, 95% CI 0.01–0.15, p = 0.017) and higher BMI (Corr. Coeff. 0.11, 95% CI 0.01–0.22, p = 0.038) were weakly associated with this outcome. Female sex (Corr. Coeff. –7.50, 95% CI –12.7– –2.20, p =0.006), higher pre-intubation SBP (Corr. Coeff. –0.09, 95% CI –0.18– –0.01, p = 0.039), and intubation for airway protection (Corr. Coeff. –1.60, 95% CI –3.10– –0.03, p = 0.046) were associated with lower prevalence of peri-intubation cardiovascular collapse.


Descargado para Lucia Angulo (lu.maru26@gmail.com) en National Library of Health and Social Security de ClinicalKey.es por Elsevier en septiembre 18, 2023. Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2023. Elsevier Inc. Todos los derechos reservados.

# а

# Study name

# Event rate and 95% CI

|                        | Event<br>rate | Lower<br>limit | Upper<br>limit | Total       |
|------------------------|---------------|----------------|----------------|-------------|
| 2006 Baillard          | 0.264         | 0.163          | 0.398          | 14 / 53     |
| 2006 Simpson           | 0.083         | 0.051          | 0.134          | 15 / 180    |
| 2008 Griesdale         | 0.191         | 0.134          | 0.266          | 26 / 136    |
| 2013 Imamura           | 0.002         | 0.001          | 0.004          | 5/3178      |
| 2013 Sakles            | 0.169         | 0.153          | 0.187          | 309 / 1828  |
| 2014 Roux              | 0.086         | 0.071          | 0.105          | 87 / 1007   |
| 2015 Mosier (a)        | 0.220         | 0.193          | 0.248          | 189 / 861   |
| 2015 Mosier (b)        | 0.281         | 0.227          | 0.342          | 66 / 235    |
| 2015 Smith             | 0.050         | 0.024          | 0.100          | 7 / 141     |
| 2016 Bodily            | 0.355         | 0.286          | 0.431          | 59 / 166    |
| 2016 Jaber             | 0.122         | 0.056          | 0.247          | 6 / 49      |
| 2016 Janz              | 0.200         | 0.144          | 0.272          | 30 / 150    |
| 2017 April             | 0.139         | 0.102          | 0.187          | 36 / 259    |
| 2017 Smischney         | 0.176         | 0.143          | 0.216          | 74 / 420    |
| 2018 Baek              | 0.025         | 0.017          | 0.037          | 24 / 958    |
| 2018 Grensemann        | 0.170         | 0.091          | 0.295          | 9 / 53      |
| 2018 Janz              | 0.229         | 0.182          | 0.284          | 60 / 262    |
| 2019 Casey             | 0.212         | 0.175          | 0.255          | 85 / 401    |
| 2019 Frat              | 0.256         | 0.210          | 0.307          | 80 / 313    |
| 2020 Chanthawatthanara | k0.007        | 0.002          | 0.029          | 2 / 267     |
| 2020 Mohr              | 0.076         | 0.071          | 0.081          | 966 / 12722 |
| 2020 Nong              | 0.226         | 0.157          | 0.316          | 24 / 106    |
| 2020 Smischney         | 0.209         | 0.185          | 0.235          | 216 / 1033  |
| 2021 Mbanjumucyo       | 0.227         | 0.174          | 0.291          | 45 / 198    |
| 2021 Russotto          | 0.092         | 0.082          | 0.103          | 272 / 2964  |
| 2021 WalimannaGamang   | e0.500        | 0.421          | 0.579          | 75 / 150    |
| 2021 Zhang             | 0.251         | 0.206          | 0.302          | 79 / 315    |
| 2022 Ergün             | 0.376         | 0.300          | 0.459          | 53 / 141    |
| Pooled                 | 0.148         | 0.115          | 0.189          |             |
| Prediction Interval    | 0.148         | 0.034          | 0.461          |             |
| Test of heter          | ogene         | itv            |                |             |



| Test of hetero | geneity |       |      |
|----------------|---------|-------|------|
| Q-value        | D(f)    | Р     | 2    |
| 1202           | 27      | 0.001 | >90% |

Fig. 3. a. Prevalence of peri-intubation hypoxia in patients undergoing intubation outside of the post-anesthesia care unit or operating room. b. Sensitivity analysis for prevalence of peri-intubation hypoxia, performed using random-effects meta-analysis with one-study-removed.

| b Name of                |        |       |       | Event rate (95% CI)      |
|--------------------------|--------|-------|-------|--------------------------|
| <b>Removed Study</b>     | 1      | Lower | Upper | with study removed       |
|                          | Point  | limit | limit |                          |
| 2006 Baillard            | 0.145  | 0.112 | 0.186 |                          |
| 2006 Simpson             | 0.151  | 0.116 | 0.194 |                          |
| 2008 Griesdale           | 0.146  | 0.113 | 0.188 | ∎                        |
| 2013 Imamura             | 0.167  | 0.131 | 0.211 |                          |
| 2013 Sakles              | 0.146  | 0.111 | 0.191 | ∎                        |
| 2014 Roux                | 0.151  | 0.116 | 0.194 | ■                        |
| 2015 Mosier (a)          | 0.145  | 0.111 | 0.187 | ∎                        |
| 2015 Mosier (b)          | 0.144  | 0.111 | 0.185 |                          |
| 2015 Smith               | 0.153  | 0.118 | 0.196 |                          |
| 2016 Bodily              | 0.143  | 0.110 | 0.183 |                          |
| 2016 Jaber               | 0.149  | 0.115 | 0.191 |                          |
| 2016 Janz                | 0.146  | 0.112 | 0.188 |                          |
| 2017 April               | 0.148  | 0.114 | 0.191 |                          |
| 2017 Smischney           | 0.147  | 0.113 | 0.189 |                          |
| 2018 Baek                | 0.158  | 0.123 | 0.201 |                          |
| 2018 Grensemann          | 0.147  | 0.113 | 0.189 |                          |
| 2018 Janz                | 0.145  | 0.112 | 0.187 |                          |
| 2019 Casey               | 0.146  | 0.112 | 0.188 |                          |
| 2019 Frat                | 0.145  | 0.111 | 0.186 |                          |
| 2020 Chanthaw atthanaral | 0.157  | 0.121 | 0.200 |                          |
| 2020 Mohr                | 0.154  | 0.121 | 0.193 |                          |
| 2020 Nong                | 0.146  | 0.112 | 0.187 |                          |
| 2020 Smischney           | 0.146  | 0.111 | 0.188 |                          |
| 2021 Mbanjumucyo         | 0.145  | 0.112 | 0.187 |                          |
| 2021 Russotto            | 0.150  | 0.114 | 0.195 |                          |
| 2021 WalimannaGamang     | e0.140 | 0.109 | 0.179 |                          |
| 2021 Zhang               | 0.145  | 0.111 | 0.186 |                          |
| 2022 Ergün               | 0.142  | 0.110 | 0.182 |                          |
| Pooled                   | 0.148  | 0.115 | 0.189 |                          |
| Prediction Interval      | 0.148  | 0.034 | 0.461 |                          |
|                          |        |       |       | 0.00 0.25 0.50 0.75 1.00 |

Fig. 3 (continued).

Reasons for intubation

Induction Medications

Pre-Intubation Interventions

## Table 4

Moderator analyses and meta-regressions for secondary outcomes of peri-intubation hypoxia and cardiac arrest.

| A. Moderator ana               | •                     | Mota analysi               | c           |                        | Listerogen | oitu    |                |                | Potwoon grou | n comparies |
|--------------------------------|-----------------------|----------------------------|-------------|------------------------|------------|---------|----------------|----------------|--------------|-------------|
| Moderator Varial               | Dies                  | Meta-analysi               |             |                        | Heterogen  |         | _              | -2             | Between grou | p compariso |
|                                |                       | # Studies                  | Outcome     | 95% CI                 | Q-value    | D(f)    | Р              | I <sup>2</sup> | Р            |             |
| Outcome: Hypox<br>Study design | ia<br>Obs prospective | 11                         | 0.08        | 0.05 0.12              | 201        | 10      | 0.001          | >90            | 0.007        |             |
| study design                   | Obs retrospective     | 11<br>9                    | 0.08<br>0.2 | 0.05–0.13<br>0.13–0.30 | 301<br>773 | 10<br>8 | 0.001<br>0.001 | >90<br>>90     | 0.007        |             |
|                                | RCT                   | 8                          | 0.2         | 0.13-0.30              | 6.8        | 7       | 0.001          | >90<br>0%      |              |             |
| Study settings                 | ED                    | 10                         | 0.21        | 0.06-0.12              | 419        | 9       | 0.45           | >90            | 0.001        |             |
| study settings                 | ICU                   | 15                         | 0.08        | 0.18-0.31              | 91         | 9<br>14 | 0.001          | >90<br>84%     | 0.001        |             |
|                                | Mixed                 | 3                          | 0.24        | 0.04-0.16              | 58         | 2       | 0.001          | 84%<br>>90     |              |             |
| WHO regions                    | AMR                   | 12                         | 0.08        | 0.04-0.18              | 72         | 2<br>11 | 0.001          | >90<br>85%     | 0.001        |             |
| vito regions                   | EUR                   | 7                          | 0.2         | 0.12-0.24              | 115        | 6       | 0.001          | >90            | 0.001        |             |
|                                | SEAR                  | 2                          | 0.18        | 0.08-0.38              | 45         | 1       | 0.001          | >90            |              |             |
|                                | WPR                   | 4                          | 0.19        |                        | 222        | 3       | 0.001          | >90<br>>90     |              |             |
|                                | Multi-national        | 2                          | 0.08        | 0.04-0.17<br>0.04-0.17 | 8          | 1       | 0.001          | >90<br>87%     |              |             |
|                                | Other                 | 2                          |             |                        |            |         |                |                |              |             |
| Sutaamaa Candia                |                       | 1                          | 0.23        | 0.08-0.49              | NA         | NA      | NA             | NA             |              |             |
| Outcome: Cardia                |                       | 14                         | 0.02        | 0.000 0.040            | 202        | 10      | 0.001          | > 00           | 0.98         |             |
| tudy design                    | Obs prospective       | 14                         | 0.02        | 0.008-0.046            | 382        | 13      | 0.001          | >90            | 0.98         |             |
|                                | Obs retrospective     | 8                          | 0.019       | 0.006-0.057            | 225        | 7       | 0.001          | >90            |              |             |
|                                | RCT                   | 6                          | 0.022       | 0.006-0.081            | 31         | 5       | 0.001          | 84%            | 0.07         |             |
| Study settings                 | ED                    | 12                         | 0.02        | 0.008-0.049            | 294        | 11      | 0.001          | >90            | 0.27         |             |
|                                | ICU<br>Minud          | 13                         | 0.014       | 0.006-0.034            | 21         | 12      | 0.053          | 42%            |              |             |
|                                | Mixed                 | 3                          | 0.068       | 0.013-0.29             | 267        | 2       | 0.001          | >90            | 0.00         |             |
| WHO regions                    | AMR                   | 13                         | 0.02        | 0.008-0.052            | 325        | 12      | 0.001          | >90            | 0.99         |             |
|                                | EUR                   | 6                          | 0.012       | 0.003-0.055            | 6          | 5       | 0.32           | 15%            |              |             |
|                                | SEAR                  | 2                          | 0.02        | 0.002-0.19             | 1          | 1       | 0.41           | 0              |              |             |
|                                | WPR                   | 5                          | 0.024       | 0.005-0.10             | 189        | 1       | 0.001          | >90            |              |             |
|                                | Multi-national        | 1                          | 0.031       | 0.001-0.54             | NA         | NA      | NA             | NA             |              |             |
|                                | Other                 | 1                          | 0.035       | 0.001-0.54             | NA         | NA      | NA             | NA             |              |             |
|                                | vascular Collapse     |                            |             |                        |            |         |                |                |              |             |
| tudy design                    | Obs prospective       | 18                         | 0.16        | 0.10-0.24              | 1622       | 17      | 0.001          | >90%           | 0.77         |             |
|                                | Obs retrospective     | 11                         | 0.19        | 0.11-0.31              | 787        | 10      | 0.001          | >90%           |              |             |
|                                | RCT                   | 8                          | 0.2         | 0.10-0.34              | 231        | 7       | 0.001          | >90%           |              |             |
| Study settings                 | ED                    | 13                         | 0.09        | 0.05-0.14              | 696        | 12      | 0.001          | >90%           | 0.002        |             |
|                                | ICU                   | 20                         | 0.25        | 0.18-0.35              | 1145       | 19      | 0.001          | >90%           |              |             |
|                                | Mixed                 | 4                          | 0.21        | 0.09-0.42              | 185        | 3       | 0.001          | >90%           |              |             |
| NHO regions                    | AMR                   | 19                         | 0.17        | 0.11-0.25              | 986        | 18      | 0.001          | >90%           | 0.069        |             |
|                                | EUR                   | 6                          | 0.24        | 0.12-0.43              | 187        | 5       | 0.001          | >90%           |              |             |
|                                | SEAR                  | 2                          | 0.19        | 0.05-0.52              | 72         | 1       | 0.001          | >90%           |              |             |
|                                | WPR                   | 6                          | 0.15        | 0.07-0.30              | 533        | 5       | 0.001          | >90%           |              |             |
|                                | Multi-national        | 2                          | 0.26        | 0.08-0.61              | 752        | 1       | 0.001          | >90%           |              |             |
|                                | Other                 | 2                          | 0.07        | 0.02-0.26              | 2.8        | 1       | 0.09           | 65%            |              |             |
| 3. Meta-Regressio              | on                    |                            |             |                        |            |         |                |                |              |             |
|                                |                       | Variables                  |             |                        | # Studies  | Cor     | rr. Coeff.     | 95%            | 6 CI         | Р           |
| Dutcome: Hypox                 | ia                    |                            |             |                        |            |         |                |                |              |             |
| Demographics                   |                       | Age (mean)                 |             |                        | 6          | 0.2     | 0              | 0.0            | 5-0.15       | 0.0         |
|                                |                       | Female (%)                 |             |                        |            | 3.9     | 0              | 0.3            | 1–7.61       | 0.0         |
|                                |                       | BMI (kg/m <sup>2,</sup> me | an)         |                        |            | -0      | ).11           | -0             | .140.07      | 0.0         |
| vital signs                    |                       | Pre-intubation S           |             | an)                    | 6          | -0      | 0.09           | -0             | .05-0.25     | 0.22        |
| Ū.                             |                       | Pre-intubation             |             |                        |            |         | 0.08           |                | .20-0.01     | 0.03        |
| Reasons for intub              | ation                 | Respiratory fail           | ure (%)     |                        | 22         | 1.1     | 0              | 0.02           | 2-2.11       | 0.0         |
|                                |                       | Airway protecti            | on (%)      |                        |            | -0      | ).30           | -2             | .03-1.40     | 0.7         |
|                                |                       | CV instability (%          | 6)          |                        |            |         | 2.30           |                | .50-1.72     | 0.2         |
| Pre-Intubation In              | terventions           | Vasopressors/In            | otropes (%) |                        | 10         | 0.8     |                |                | .40-2.99     | 0.4         |
|                                |                       | Preoxygenation             |             |                        | 7          | 4.1     |                |                | .77-8.90     | 0.1         |
|                                |                       | Preoxygenation             | · · ·       |                        |            |         | 0.04           |                | .10-4.00     | 0.9         |
| nduction Medica                | itions                | Propofol (%)               |             |                        | 7          | 9.4     |                |                | 0–17.1       | 0.0         |
| induction medice               |                       | Etomidate (%)              |             |                        |            | 0.7     |                |                | .20-3.60     | 0.64        |
|                                |                       | Midazolam (%)              |             |                        |            |         | 1.7            |                | 1.42.10      | 0.0         |
| Paralytics                     |                       | Succinylcholine            | (%)         |                        | 10         | 7.2     |                |                | 0-9.80       | 0.0         |
| ararytics                      |                       | Rocuronium (%              |             |                        |            | 4.4     |                |                | 0-5.70       | 0.0         |
| Outcome: Cardia                | c Arrest              |                            | /           |                        |            | 1,-1    | -              | 5.1            | - 30.0       | 0.0         |
| Demographics                   |                       | Age (mean)                 |             |                        | 11         | (       | 0.10           | 0              | .33-0.08     | 0.2         |
| 2 emographics                  |                       | Female (%)                 |             |                        | ••         | 2.1     |                |                | 7.4–21.7     | 0.2         |
|                                |                       | BMI (kg/m <sup>2,</sup> me | an)         |                        |            |         | 0.03           |                | .40-0.37     | 0.8         |
| vital signs                    |                       | Pre-intubation S           |             | (ne                    | 8          |         | ).03           |                | .07-0.02     | 0.3         |
| itui sigiis                    |                       | Pre-intubation             |             | ,                      | 0          | -0.1    |                |                | 1-0.25       | 0.0         |
| Reasons for intub              | ation                 | Respiratory fail           |             |                        | 23         | 0.1     |                |                | 80-2.60      | 0.0         |
| JEASOUS (OF INFILE             | an off                | RESULTATORY (ALL)          | 1151/61     |                        | Z 1        | 04      | 47             | - 1            | 04-2.00      | U / !       |

23

13

7

6

0.40

-0.22

-0.10

-3.40

-7.30

3.03

5.20

-1.80 - 2.60

-3.50 - 3.01

-3.10 - 2.90

-8.40 - 1.72

-18.2-3.60

-8.26-12.3

-2.80-13.2

0.71

0.89 0.95

0.2

0.19

0.6

0.2

Respiratory failure (%)

Airway protection (%)

Vasopressors/Inotropes (%)

Preoxygenation with NIV (%)

Preoxygenation with HFNC (%)

CV instability (%)

Propofol (%)

### Table 4 (continued)

|                              | Variables                       | # Studies | Corr. Coeff. | 95% CI       | Р     |
|------------------------------|---------------------------------|-----------|--------------|--------------|-------|
|                              | Etomidate (%)                   |           | -2.70        | -5.200.13    | 0.04  |
|                              | Midazolam (%)                   |           | -5.60        | -14.2 - 2.90 | 0.2   |
| Paralytics                   | Succinylcholine (%)             | 12        | 1.60         | -3.10-6.40   | 0.5   |
|                              | Rocuronium (%)                  |           | 2.40         | -3.20-8.10   | 0.4   |
| Demographics                 | Age (mean)                      | 8         | 0.08         | 0.01-0.15    | 0.017 |
|                              | Female (%)                      |           | -7.50        | -12.72.20    | 0.006 |
|                              | BMI (kg/m <sup>2</sup> mean)    |           | 0.11         | 0.01-0.22    | 0.038 |
| Vital signs                  | Pre-intubation SBP (mmHg, mean) | 9         | -0.09        | -0.18 - 0.01 | 0.039 |
| -                            | Pre-intubation HR (bpm, mean)   |           | -0.13        | -0.10 - 0.07 | 0.77  |
| Reasons for intubation       | Respiratory failure (%)         | 33        | 1.20         | 0.00-2.30    | 0.05  |
|                              | Airway protection (%)           |           | -1.60        | -3.100.03    | 0.046 |
|                              | CV instability (%)              |           | 2.90         | 0.91-4.80    | 0.004 |
| Pre-Intubation Interventions | Vasopressors/Inotropes (%)      | 17        | 2.50         | -0.80-5.70   | 0.14  |
|                              | Preoxygenation with NIV (%)     | 7         | 1.20         | -4.10-6.50   | 0.67  |
|                              | Preoxygenation with HFNC (%)    |           | 1.50         | -2.80 - 5.90 | 0.49  |
| Induction Medications        | Propofol (%)                    | 10        | 7.50         | 3.20-11.7    | 0.001 |
|                              | Etomidate (%)                   |           | 1.20         | -0.49 - 2.90 | 0.16  |
|                              | Midazolam (%)                   |           | -0.86        | -3.50 - 1.70 | -0.52 |
| Paralytics                   | Succinylcholine (%)             | 16        | 5.60         | 1.90-9.30    | 0.003 |
| -                            | Rocuronium (%)                  |           | -1.70        | -5.90 - 2.40 | 0.41  |

Abbreviations: RCT, randomized control trial; ED, emergency department; ICU, intensive care unit; WHO, World Health Organization; AMR, Region of the Americas; EUR, European Region; SEAR, South-East Asian Region; WPR, Western Pacific Region; BMI, body mass index; CV, cardiovascular; NIV, non-invasive ventilation; HFNC, high-flow nasal cannula.

## 4. Discussion

Our findings suggest that approximately 1 in 3 patients undergoing intubation in the ED, the ICU or medical wards will experience a clinically significant peri-intubation adverse event, including hypoxia, cardiovascular instability, or cardiac arrest. Fifteen percent of these patients experienced hypoxia, 18% cardiovascular instability, and 2% cardiac arrest. Our exploratory multivariable meta-regression also identified intubation for hemodynamic instability and use of propofol or succinylcholine for inductionas independent risk factors associated with a higher prevalence of peri-intubation MAEs, and specifically with higher rates of peri-intubation hypoxia and cardiovascular collapse. Intubation for airway protection was correlated with a lower prevalence of periintubation MAEs.

High heterogeneity was observed in this meta-analysis and across many subgroup analyses, likely due to differences in studies' clinical setting and patient selection: while many studies reported data for allcomers, others focused only on critically ill patients or those anticipated to have difficult airways, and still others on those with specific diseaseentities, such as COVID-19. This resulted in a wide range of reported rates of MAEs, from 2% by Imamura et al. in 2013 to 98% by Walimanna Gamange et al. in 2021. However, this meta-analysis indicated that across a wide variety of patient populations and clinical settings similar to the included studies, the prevalence for composite MAEs would range from 22% to 38%.

The ED and ICU are the most studied (and likely most common) settings in which patients are intubated outside the OR or PACU and have significantly different rates of adverse events: 17% in the ED as opposed to 23% in the ICU. We expect this is primarily reflective of distinct patient populations (the ICU by default selects a more critically ill subset of patients) and clinical scenarios surrounding intubation: 28% of ICU patients were intubated for respiratory failure, compared to 7% of ED patients.Wwhile intubation for respiratory failure did not meet statistical significance as a risk factor for peri-intubation MAE, it was associated with an increased risk of hypoxia. Moreover, we did see a trend towards increased risk of overall MAEs in this population (Corr. Coeff. 0.9, 95% CI -0.01 to 1.8, p = 0.05). Furthermore, almost two-thirds of included patients intubated in the ED were intubated for "other" reasons (i.e., not respiratory failure, airway protection, hemodynamic instability, or cardiac arrest), which often included facilitation of procedures in patients who may have been otherwise relatively healthy. Seven percent of ED intubations occurred in the setting of cardiac arrest, compared to just under 1% of ICU intubations. In the absence of return of spontaneous circulation, it is likely that patients intubated for cardiac arrest woul not be counted as experiencing any periintubation MAEs. Regardless, the high rates of MAEs seen here should encourage all physicians to carefully consider and prepare for MAEs during and following all intubations.

In general, the risk factors identified here as contributors to various peri-intubation MAEs are common indicators of overall critical illness and risk for a variety of adverse events, most notably, intubation for pre-existing respiratory failure or hemodynamic instability. Older patients were also found to be at higher risk of peri-intubation hypoxia. Interestingly, increased BMI was associated with a lower risk of periintubation hypoxia, but a higher risk of peri-intubation cardiovascular collapse. Obesity has been recognized as a herald of an anatomically difficult airway and has previously been associated with increased periintubation complications in the ICU [48]. Of the 9 studies included in this meta-analysis that reported mean BMI, only two reported mean BMIs in the "obese" category (>30 kg/m<sup>2</sup>). It is difficult to say what this apparent protective feature of elevated BMI with respect to hypoxia reflects-for example, increased precautions during the intubation of obese patients due to anticipated difficult airways, or a lower percentage of underweight or cachectic patients.

Induction medications - both sedatives and NMB - were also associated with rates of overall MAEs, hypoxia, and cardiac arrest. The studies investigating these agents were primarily observational; as such, it is difficult to determine if these findings reflect a true risk associated with these medications or physicians' assessment of risk prior to induction (that is, physicians may have been more likely to use certain agents in what they perceived to be higher risk intubations). We found propofol was associated with higher rates of overall MAEs and hypoxia. While propofol has not been commonly associated with higher risks of hypoxia in previous literature, it has been associated with hypotension: tThe multicenter observational INTUBE study, published in 2021 and included in this meta-analysis, identified use of propofol as the only modifiable factor associated with increased risk of peri-intubation cardiovascular instability or collapse [68]. In our analysis, use of midazolam was associated with a lower rate of peri-intubation hypoxia, and etomidate with a lower rate of peri-intubation cardiac arrest. The

# а

Study name

# Event rate and 95% CI

|  | Event<br>rate  | Lower<br>limit | Upper<br>limit | Total                 |            |     |     |   |   | ative<br>eight |
|--|----------------|----------------|----------------|-----------------------|------------|-----|-----|---|---|----------------|
| 2006 Simpson                                   | 0.011          | 0.003          | 0.043          | 2 / 180               | •          |     |     | 1 | 1 | 3.34           |
| 2008 Griesdale                                 | 0.449          | 0.367          | 0.533          | 61 / 136              |            |     | -∎- |   |   | 4.11           |
| 2011 Mayo                                      | 0.008          | 0.001          | 0.053          | 1 / 128               | <b>⊨</b> - |     |     |   |   | 2.78           |
| 2013 Heffner                                   | 0.041          | 0.026          | 0.066          | 17/410                |            |     |     |   |   | 4.05           |
| 2013 Imamura                                   | 0.001          | 0.000          | 0.003          | 4 / 3178              |            |     |     |   |   | 3.71           |
| 2013 Sakles                                    | 0.002          | 0.001          | 0.005          | 3 / 1828              | •          |     |     |   |   | 3.58           |
| 2015 Mosier (a)                                | 0.005          | 0.002          | 0.012          | 4 / 861               |            |     |     |   |   | 3.71           |
| 2015 Smith                                     | 0.004          | 0.000          | 0.054          | 0/141                 |            |     |     |   |   | 2.09           |
| 2016 Cham                                      | 0.012          | 0.005          | 0.032          | 4 / 325               | •          |     |     |   |   | 3.71           |
| 2016 Jaber                                     | 0.010          | 0.001          | 0.141          | 0 / 49                |            |     |     |   |   | 2.08           |
| 2016 Janz                                      | 0.013          | 0.003          | 0.052          | 2 / 150               | -          |     |     |   |   | 3.33           |
| 2016 Ono                                       | 0.041          | 0.017          | 0.094          | 5 / 123               |            |     |     |   |   | 3.78           |
| 2017 April                                     | 0.039          | 0.021          | 0.070          | 10/259                |            |     |     |   |   | 3.97           |
| 2018 Corl                                      | 0.011          | 0.004          | 0.033          | 3 / 275               | - <b>e</b> |     |     |   |   | 3.58           |
| 2018 De Jong                                   | 0.027          | 0.020          | 0.035          | 49 / 1847             |            |     |     |   |   | 4.13           |
| 2018 Driver                                    | 0.073          | 0.056          | 0.093          | 55/757                |            |     |     |   |   | 4.14           |
| 2018 Janz                                      | 0.027          | 0.013          | 0.055          | 7 / 262               |            |     |     |   |   | 3.89           |
| 2019 Casey                                     | 0.015          | 0.007          | 0.033          | 6 / 401               | -          |     |     |   |   | 3.85           |
| 2019 Frat                                      | 0.019          | 0.009          | 0.042          | 6/313                 |            |     |     |   |   | 3.85           |
| 2020 Amatric                                   | 0.010          | 0.002          | 0.039          | 2 / 202               | - <b>1</b> |     |     |   |   | 3.34           |
| 2020 Chantha watthanarah                       | 0.015          | 0.006          | 0.039          | 4 / 267               |            |     |     |   |   | 3.71           |
| 2020 de Alencar                                | 0.018          | 0.004          | 0.069          | 2/112                 | -          |     |     |   |   | 3.33           |
| 2021 Mbanjumucyo                               | 0.035          | 0.017          | 0.072          | 7 / 198               | -          |     |     |   |   | 3.89           |
| 2021 Russotto                                  | 0.031          | 0.026          | 0.038          | 93 / 2964             |            |     |     |   |   | 4.15           |
| 2021 Walimanna Gamange                         | 0.027          | 0.010          | 0.069          | 4 / 150               | -          |     |     |   |   | 3.70           |
| 2021 Zhang                                     | 0.032          | 0.017          | 0.058          | 10/315                | -          |     |     |   |   | 3.97           |
| 2022 Ergün                                     | 0.004          | 0.000          | 0.054          | 0 / 141               | •          |     |     |   |   | 2.09           |
| 2022 Yang                                      | 0.250          | 0.208          | 0.297          | 92/368                |            |     |     |   |   | 4.15           |
| Pooled   | 0.020          | 0.012          | 0.035          |                       | +          |     |     |   |   |                |
| Prediction Interval                            | 0.020          | 0.001          | 0.288          |                       |            | -+- |     |   |   |                |
| Test of heterogeneity 0.00 0.25 0.50 0.75 1.00 |                |                |                |                       |            |     |     |   |   |                |
|  | Q-value D(f) P |                | Р              | <b> </b> <sup>2</sup> |            |     |     |   |   |                |
| 71   | 5              | 27 (           | 0.001          | >90%                  |            |     |     |   |   |                |

Fig. 4. a. Prevalence of peri-intubation cardiac arrest in patients undergoing intubation outside of the post-anesthesia care unit or operating room. b.Sensitivity analysis for prevalence of peri-intubation cardiac arrest, performed using random-effects meta-analysis with one-study-removed.

Name of

b

Event rate (95% CD

| Name of                 |        |             |       | Event l'ate (95% CI) |      |      |       |      |  |
|-------------------------|--------|-------------|-------|----------------------|------|------|-------|------|--|
| Removed Study           |        | Lower Upper |       | with study removed   |      |      |       |      |  |
|                         | Point  | limit       | limit |                      |      |      |       |      |  |
| 2006 Simpson            | 0.021  | 0.012       | 0.036 |                      | Ĩ    | 1    | - I - |      |  |
| 2008 Griesdale          | 0.018  | 0.011       | 0.029 |                      |      |      |       |      |  |
| 2011 Mayo               | 0.021  | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2013 Heffner            | 0.020  | 0.011       | 0.035 |                      |      |      |       |      |  |
| 2013 Imamura            | 0.023  | 0.013       | 0.039 |                      |      |      |       |      |  |
| 2013 Sakles             | 0.022  | 0.013       | 0.039 |                      |      |      |       |      |  |
| 2015 Mosier (a)         | 0.022  | 0.012       | 0.037 | -                    |      |      |       |      |  |
| 2015 Smith              | 0.021  | 0.012       | 0.037 |                      |      |      |       |      |  |
| 2016 Cham               | 0.021  | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2016 Jaber              | 0.021  | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2016 Janz               | 0.021  | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2016 Ono                | 0.020  | 0.011       | 0.035 |                      |      |      |       |      |  |
| 2017 April              | 0.020  | 0.011       | 0.035 |                      |      |      |       |      |  |
| 2018 Corl               | 0.021  | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2018 De Jong            | 0.020  | 0.011       | 0.036 |                      |      |      |       |      |  |
| 2018 Driver             | 0.019  | 0.010       | 0.035 |                      |      |      |       |      |  |
| 2018 Janz               | 0.020  | 0.011       | 0.035 |                      |      |      |       |      |  |
| 2019 Casey              | 0.021  | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2019 Frat               | 0.020  | 0.011       | 0.036 |                      |      |      |       |      |  |
| 2020 Amalric            | 0.021  | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2020 Chanthawatthanaral | x0.021 | 0.012       | 0.036 |                      |      |      |       |      |  |
| 2020 de Alencar         | 0.020  | 0.012       | 0.036 | -                    |      |      |       |      |  |
| 2021 Mbanjumucyo        | 0.020  | 0.011       | 0.035 |                      |      |      |       |      |  |
| 2021 Russotto           | 0.020  | 0.011       | 0.036 |                      |      |      |       |      |  |
| 2021 WalimannaGamang    | e0.020 | 0.011       | 0.035 |                      |      |      |       |      |  |
| 2021 Zhang              | 0.020  | 0.011       | 0.035 |                      |      |      |       |      |  |
| 2022 Ergün              | 0.021  | 0.012       | 0.037 |                      |      |      |       |      |  |
| 2022 Yang               | 0.018  | 0.011       | 0.031 |                      |      |      |       |      |  |
| Pooled                  | 0.020  | 0.012       | 0.035 | +                    |      |      |       |      |  |
| Prediction Interval     | 0.020  | 0.001       | 0.288 | $\vdash$             | +    |      |       | 1    |  |
|                         |        |             |       | 0.00                 | 0.25 | 0.50 | 0.75  | 1.00 |  |

Fig. 4 (continued).

association between midazolam and a lower rate of hypoxia was unexpected, given the known association between benzodiazepines and respiratory depression. Etomidate is recognized as having a relatively neutral hemodynamic profile, and has been previously associated with relatively lower rates of peri-intubation hypotension in the Emergency Department [69].

Administration of any NMB was associated with a higher rate of periintubation hypoxia, while only succinylcholine was associated with increased risk of overall MAEs. The association of NMB with hypoxia may be due to suppression of respiratory drive, especially in patients with poor respiratory reserve (such as those with obesity, restrictive lung disease, or COVID-19) or in patients who were not pre-oxygenated or were inadequately pre-oxygenated prior to induction [70,71]. Succinylcholine has previously been associated with a wider range of adverse effects than rocuronium, including hyperkalemia [72], arrhythmias, fasciculations, and malignant hyperthermia [73]. A 2019 RCT investigating success of out-of-hospital intubation using either succinylcholine or rocuronium found fewer complications (including arrhythmias and hypotension) among patients intubated with rocuronium [74]. Despite this, succinylcholine has been suggested to more reliably create optimal conditions for intubation, and as such remains recommended as firstline for intubation of patients for whom there are no known contraindications to its use [75].

## 4.1. Limitations

The findings presented here are limited by the lack of consensus regarding the definitions of important major adverse events, including hypoxia, hypotension, and hemodynamic instability. The included studies used a variety of different thresholds for each criterion; as such, our findings are influenced by their definitions as well as the authors' data. This lack of consensus also increased the heterogeneity of this metaanalysis. Other outcomes, such as administration of IVF boluses or vasopressors, may directly be reflective of physicians' decisions, rather than a direct measure of patient status, and thus may be influenced by individual or institutional practice patterns. Finally, the outcomes of periintubation hypoxia and hypotension are not in themselves necessarily patient-oriented, though prior research has drawn a clear connection between these metrics and in-hospital mortality [5-8].

Several included studies did not report a comprehensive set of pre-intubation vital signs or interventions, limiting our ability to adequately characterize patients' clinical status prior to intubation and thus their risk. Moreover, data was not reported in such a way that allowed us to perform subgroup analyses of patients with or without pre-intubation hypoxia or cardiovascular instability, who would reasonably be expected to be at high risk of these clinical outcomes in the peri-intubation period as well. This may reflect a historic focus in the airway literature on the anatomically difficult airway and physicians' technical capability in achieving "first pass success", as opposed to the more nuanced resuscitative monitoring and treatment involved in the management of the physiologically difficult airway.

## 4.2. Implications for future research

Our analysis highlights the prevalence of peri-intubation MAEs across intubations occurring outside the OR or PACU, particularly in the ICU. Additional research is needed to evaluate potential interventions to prevent these adverse events. Many studies did not report in detail many known risk factors for peri-intubation MAE: obesity and severe acidosis have been reported as known risk factors [76,77] for the "physiologically difficult airway" but a majority of studies did not report this information. Further studies about periintubation should pay attention and report the risk factors for "physiologically difficult airway" to help physicians prepare for caring of critically ill patients.

# 5. Conclusions

Peri-intubation adverse events occur in almost one third of all intubations in the ED, ICU or medical wards. They are more common in the ICU and among patients with pre-existing hemodynamic compromise. Physicians should evaluate all patients for the likelihood of a physiologically difficult airway prior to intubation, and plan appropriately and accordingly for potential hypoxia, hypotension, or cardiac arrest in the peri-intubation period.

Supplementary data to this article can be found online at https://doi. org/10.1016/j.ajem.2023.06.046.

# **CRediT** authorship contribution statement

Jessica Downing: Writing – review & editing, Writing – original draft, Validation, Supervision, Project administration, Methodology, Investigation, Data curation. Isha Yardi: Validation, Project administration, Data curation. Christine Ren: Writing – review & editing, Validation, Supervision, Project administration, Methodology, Data curation. Stephanie Cardona: Writing – review & editing, Validation, Supervision, Project administration, Methodology, Data curation. Stephanie Cardona: Writing – review & editing, Validation, Supervision, Project administration, Methodology, Data curation. Manahel Zahid: Validation, Data curation. Kaitlyn Tang: Validation, Data curation. Vera Bzhilyanskaya: Validation, Data curation. Priya Patel: Validation, Data curation. Ali Pourmand: Methodology, Conceptualization. Quincy K. Tran: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Formal analysis, Conceptualization.

## **Declaration of Competing Interest**

The authors have no conflicts of interest to disclose.

## References

- Hsiao YJ, Chen CY, Hung HT, et al. Comparison of the outcome of emergency endotracheal intubation in the general ward, intensive care unit and emergency department. Biom J. 2021;44(6 Suppl 1):S110–8. https://doi.org/10.1016/j.bj.2020.07.006.
- [2] Russotto V, Myatra SN, Laffey JG, et al. Intubation practices and adverse Periintubation events in critically ill patients from 29 countries. JAMA. 2021;325(12): 1164–72. https://doi.org/10.1001/jama.2021.1727.
- [3] Mosier JM, Joshi R, Hypes C, Pacheco G, Valenzuela T, Sakles JC. The physiologically difficult airway. West J Emerg Med. 2015;16(7):1109–17. https://doi.org/10.5811/ westjem.2015.8.27467.
- [4] Sakles JC, Pacheco GS, Kovacs G, Mosier JM. The difficult airway refocused. Br J Anaesth. 2020;125(1):e18–21. https://doi.org/10.1016/j.bja.2020.04.008.
- [5] Smischney NJ, Khanna AK, Brauer E, et al. Risk factors for and outcomes associated with Peri-intubation hypoxemia: a multicenter prospective cohort study. J Intensive Care Med. 2021;36(12):1466–74. https://doi.org/10.1177/0885066620962445.
- [6] Heffner AC, Swords D, Kline JA, Jones AE. The frequency and significance of postintubation hypotension during emergency airway management. J Crit Care. 2012;27(4):417.e9–417.e13. https://doi.org/10.1016/j.jcrc.2011.08.011.
- [7] Heffner AC, Swords DS, Neale MN, Jones AE. Incidence and factors associated with cardiac arrest complicating emergency airway management. Resuscitation. 2013; 84(11):1500–4. https://doi.org/10.1016/j.resuscitation.2013.07.022.
- [8] Ferrada P, Manzano-Nunez R, Lopez-Castilla V, et al. Meta-analysis of postintubation hypotension: a Plea to consider circulation first in hypovolemic patients. Am Surg. 2019;85(2):167–72.
- [9] Cook TM, Woodall N, Harper J, Benger J, Fourth National Audit Project. Major complications of airway management in the UK: results of the fourth National Audit Project of the Royal College of Anaesthetists and the difficult airway society. Part 2: intensive care and emergency departments. Br J Anaesth. 2011;106(5):632–42. https:// doi.org/10.1093/bja/aer059.
- [10] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https://doi.org/10. 1136/bmj.n71.
- [11] Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. https:// doi.org/10.1136/bmj.d5928.
- [12] Wella G, Shea B, O'Connell D, Peterson J, Welch V, Losos TT, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in metaanalyse; 2000. Accessed August 2, 2019. http://www.ohri.ca/programs/ clinical\_epidemiology/oxford.asp.
- [13] Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27 (6):1785–805. https://doi.org/10.1177/0962280216669183.
- [14] Borenstein M. Common Mistakes in Meta-Analysis and How to Avoid Them; 2019.

- [15] Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixedeffect and random-effects models for meta-analysis. Res Synth Methods. 2010;1 (2):97–111. https://doi.org/10.1002/jrsm.12.
- [16] Borenstein M, editor. Introduction to Meta-analysis. John Wiley & Sons; 2009.
- [17] Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. Psychol Methods. 1998;3(4):486–504. https://doi.org/10.1037/1082-989X.3.4.486.
- [18] Higgins JPT, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Wiley-Blackwell; 2020.
- [19] Borenstein M. Research note: in a meta-analysis, the I index does not tell us how much the effect size varies across studies. J Physiother. 2020;66(2):135–9. https:// doi.org/10.1016/j.jphys.2020.02.011.
- [20] Borenstein M, Higgins JPT, Hedges LV, Rothstein HR. Basics of meta-analysis: 1<sup>2</sup> is not an absolute measure of heterogeneity: 1<sup>2</sup> is not an absolute measure of heterogeneity. Res Synth Methods. 2017;8(1):5–18. https://doi.org/10.1002/jrsm.1230.
- [21] DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139–45. https://doi.org/10.1016/j.cct.2015.09.002.
- [22] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7 (3):177–88. https://doi.org/10.1016/0197-2456(86)90046-2.
- [23] Higgins JPT. Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2008;37(5):1158–60. https://doi.org/10. 1093/ije/dyn204.
- [24] Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.
- [25] Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414): 557-60. https://doi.org/10.1136/bmj.327.7414.557.
- [26] IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6(7):e010247. https://doi.org/10. 1136/bmjopen-2015-010247.
- [27] Baillard C, Fosse JP, Sebbane M, et al. Noninvasive ventilation improves Preoxygenation before intubation of hypoxic patients. Am J Respir Crit Care Med. 2006;174(2):171–7. https://doi.org/10.1164/rccm.200509-15070C.
- [28] Jaber S, Monnin M, Girard M, et al. Apnoeic oxygenation via high-flow nasal cannula oxygen combined with non-invasive ventilation preoxygenation for intubation in hypoxaemic patients in the intensive care unit: the single-Centre, blinded, randomised controlled OPTINIV trial. Intensive Care Med. 2016;42(12):1877–87. https://doi.org/10.1007/s00134-016-4588-9.
- [29] Janz DR, Semler MW, Lentz RJ, et al. Randomized trial of video laryngoscopy for endotracheal intubation of critically ill adults\*. Crit Care Med. 2016;44(11):1980–7. https://doi.org/10.1097/CCM.000000000001841.
- [30] Driver BE, Prekker ME, Klein LR, et al. Effect of use of a Bougie vs endotracheal tube and stylet on first-attempt intubation success among patients with difficult airways undergoing emergency intubation: a randomized clinical trial. JAMA. 2018;319(21): 2179. https://doi.org/10.1001/jama.2018.6496.
- [31] Grensemann J, Eichler L, Wang N, Jarczak D, Simon M, Kluge S. Endotracheal tubemounted camera-assisted intubation versus conventional intubation in intensive care: a prospective, randomised trial (VivaITN). Crit Care. 2018;22(1):235. https:// doi.org/10.1186/s13054-018-2152-4.
- [32] Janz DR, Semler MW, Joffe AM, et al. A multicenter randomized trial of a checklist for endotracheal intubation of critically ill adults. Chest. 2018;153(4):816–24. https:// doi.org/10.1016/j.chest.2017.08.1163.
- [33] Casey JD, Janz DR, Russell DW, et al. Bag-mask ventilation during tracheal intubation of critically ill adults. N Engl J Med. 2019;380(9):811–21. https://doi.org/10.1056/ NEJMoa1812405.
- [34] Frat JP, Ricard JD, Quenot JP, et al. Non-invasive ventilation versus high-flow nasal cannula oxygen therapy with apnoeic oxygenation for preoxygenation before intubation of patients with acute hypoxaemic respiratory failure: a randomised, multicentre, open-label trial. Lancet Respir Med. 2019;7(4):303–12. https://doi.org/10. 1016/S2213-2600(19)30048-7.
- [35] Nong L, Liang W, Yu Y, et al. Noninvasive ventilation support during fiberoptic bronchoscopy-guided nasotracheal intubation effectively prevents severe hypoxemia. J Crit Care. 2020;56:12–7. https://doi.org/10.1016/j.jcrc.2019.10.017.
- [36] Khan FH, Khan FA, Irshad R, Kamal RS. Complications of endotracheal intubation in mechanically ventilated patients in a general intensive care unit. JPMA J Pak Med Assoc. 1996;46(9):195–8.
- [37] Simpson J. Rapid sequence intubation in the emergency department: 5 year trends. Emerg Med J. 2006;23(1):54–6. https://doi.org/10.1136/emj.2004.019398.
- [38] Griesdale DEG, Bosma TL, Kurth T, Isac G, Chittock DR. Complications of endotracheal intubation in the critically ill. Intensive Care Med. 2008;34(10):1835–42. https://doi. org/10.1007/s00134-008-1205-6.
- [39] Mayo PH, Hegde A, Eisen LA, Kory P, Doelken P. A program to improve the quality of emergency endotracheal intubation. J Intensive Care Med. 2011;26(1):50–6. https:// doi.org/10.1177/0885066610384070.
- [40] Imamura T, Brown CA, Ofuchi H, et al. Emergency airway management in geriatric and younger patients: analysis of a multicenter prospective observational study. Am J Emerg Med. 2013;31(1):190–6. https://doi.org/10.1016/j.ajem.2012.07.008.
- [41] Roux D, Reignier J, Thiery G, et al. Acquiring procedural skills in ICUs: a prospective multicenter study\*. Crit Care Med. 2014;42(4):886–95. https://doi.org/10.1097/ CCM.000000000000049.
- [42] Mosier JM, Malo J, Sakles JC, et al. The impact of a comprehensive airway management training program for pulmonary and critical care medicine fellows. A threeyear experience. Ann Am Thorac Soc. 2015;12(4):539–48. https://doi.org/10.1513/ AnnalsATS.201501-0230C.
- [43] Smith KA, High K, Collins SP, Self WH. A Preprocedural checklist improves the safety of emergency department intubation of trauma patients. Reardon R, ed. Acad Emerg Med. 2015;22(8):989–92. https://doi.org/10.1111/acem.12717.

- [44] Bodily JB, Webb HR, Weiss SJ, Braude DA. Incidence and duration of continuously measured oxygen desaturation during emergency department intubation. Ann Emerg Med. 2016;67(3):389–95. https://doi.org/10.1016/j.annemergmed.2015.06. 006.
- [45] Sakles JC, Mosier JM, Patanwala AE, Dicken JM. Apneic oxygenation is associated with a reduction in the incidence of hypoxemia during the RSI of patients with intracranial hemorrhage in the emergency department. Intern Emerg Med. 2016;11(7): 983–92. https://doi.org/10.1007/s11739-016-1396-8.
- [46] April MD, Schauer SG, Brown Rd CA, et al. A 12-month descriptive analysis of emergency intubations at Brooke Army medical center: a National Emergency Airway Registry study. US Army Med Dep J. 2017;3-17:98–104.
- [47] Corl KA, Dado C, Agarwal A, et al. A modified Montpellier protocol for intubating intensive care unit patients is associated with an increase in first-pass intubation success and fewer complications. J Crit Care. 2018;44:191–5. https://doi.org/10.1016/j. jcrc.2017.11.014.
- [48] De Jong A, Rolle A, Molinari N, et al. Cardiac arrest and mortality related to intubation procedure in critically ill adult patients: a multicenter cohort study. Crit Care Med. 2018;46(4):532–9. https://doi.org/10.1097/CCM.00000000002925.
- [49] Amalric M, Larcher R, Brunot V, et al. Impact of Videolaryngoscopy expertise on firstattempt intubation success in critically ill patients. Crit Care Med. 2020;48(10): e889–96. https://doi.org/10.1097/CCM.000000000004497.
- [50] Chanthawatthanarak S, Tangpaisarn T, Kotruchin P, Phungoen P, lenghong K, Apiratwaraku K. First-pass success rates of endotracheal intubation using ramped versus supine positioning in the emergency department. J Med Assoc Thai. 2020; 103(6):51–7.
- [51] JCG Alencar, Marques B, Marchini JFM, et al. First-attempt intubation success and complications in patients with COVID-19 undergoing emergency intubation. J Am Coll Emerg Physicians Open. 2020;1(5):699–705. https://doi.org/10.1002/emp2. 12219.
- [52] Mbanjumucyo G, Aluisio A, Cattermole GN. Characteristics, physiology and mortality of intubated patients in an emergency care population in sub-Saharan Africa: a prospective cohort study from Kigali, Rwanda. Emerg Med J. 2021;38(3):178–83. https://doi.org/10.1136/emermed-2019-208521.
- [53] Walimanna Gamage RJK. Endotracheal intubation in critically ill patients, practices, complications and factors associated with post intubation hypotension: a study in National Hospital Sri Lanka. Sri Lankan J Anaesthesiol. 2020;28(2):101. https://doi. org/10.4038/slja.v28i2.8569.
- [54] Zhang C, Ou M. Comparison of hypoxemia, intubation procedure, and complications for non-invasive ventilation against high-flow nasal cannula oxygen therapy for patients with acute hypoxemic respiratory failure: a non-randomized retrospective analysis for effectiveness and safety (NIVaHIC-aHRF). BMC Emerg Med. 2021;21 (1):6. https://doi.org/10.1186/s12873-021-00402-w.
- [55] Smischney NJ, Seisa MO, Cambest J, et al. The incidence of and risk factors for Postintubation hypotension in the immunocompromised critically ill adult. J Intensive Care Med. 2019;34(7):578–86. https://doi.org/10.1177/0885066617704844.
- [56] Green RS, Edwards J, Sabri E, Fergusson D. Evaluation of the incidence, risk factors, and impact on patient outcomes of postintubation hemodynamic instability. CJEM. 2012;14(02):74–82. https://doi.org/10.2310/8000.2012.110548.
- [57] Sakles JC, Chiu S, Mosier J, Walker C, Stolz U. The importance of first pass success when performing Orotracheal intubation in the emergency department. Reardon RF, ed. Acad Emerg Med. 2013;20(1):71–8. https://doi.org/10.1111/acem.12055.
- [58] Mosier JM, Sakles JC, Whitmore SP, et al. Failed noninvasive positive-pressure ventilation is associated with an increased risk of intubation-related complications. Ann Intensive Care. 2015;5(1):4. https://doi.org/10.1186/s13613-015-0044-1.
- [59] Trivedi S, Demirci O, Arteaga G, Kashyap R, Smischney NJ. Evaluation of preintubation shock index and modified shock index as predictors of postintubation hypotension and other short-term outcomes. J Crit Care. 2015;30(4):861.e1–7. https://doi.org/10.1016/j.jcrc.2015.04.013.
- [60] Cham E, Wong O, Yip K. Clinical practice and risk factors for immediate complications of endotracheal intubation by intensive care unit doctors in a regional Hospital in Hong Kong. Hong Kong J Emerg Med. 2016;23(3):135–44. https://doi.org/10. 1177/102490791602300302.
- [61] Ono Y, Sugiyama T, Chida Y, et al. Association between off-hour presentation and endotracheal-intubation-related adverse events in trauma patients with a predicted difficult airway: a historical cohort study at a community emergency department in Japan. Scand J Trauma Resusc Emerg Med. 2016;24(1):106. https://doi.org/10.1186/ s13049-016-0296-2.
- [62] Smischney NJ, Seisa MO, Heise KJ, et al. Predictors of arterial desaturation during intubation: a nested case-control study of airway management—part I. J Thorac Dis. 2017;9(10):3996–4005. https://doi.org/10.21037/jtd.2017.08.138.
- [63] Van Berkel MA, Exline MC, Cape KM, et al. Increased incidence of clinical hypotension with etomidate compared to ketamine for intubation in septic patients: a propensity matched analysis. J Crit Care. 2017;38:209–14. https://doi.org/10.1016/j.jcrc. 2016.11.009.
- [64] Baek MS, Han M, Huh JW, Lim CM, Koh Y, Hong SB. Video laryngoscopy versus direct laryngoscopy for first-attempt tracheal intubation in the general ward. Ann Intensive Care. 2018;8(1):83. https://doi.org/10.1186/s13613-018-0428-0.
- [65] Mohr NM, Pape SG, Runde D, Kaji AH, Walls RM, Brown CA. Etomidate use is associated with less hypotension than ketamine for emergency department Sepsis intubations: a NEAR cohort study. Reardon R, ed. Acad Emerg Med. 2020;27(11):1140–9. https://doi.org/10.1111/acem.14070.
- [66] Ergün B, Ergan B, Yakar MN, et al. Incidência e fatores de risco para hipotensão pósintubação em pacientes críticos com COVID-19. Rev Bras Ter Intensiva. 2022;34(1). https://doi.org/10.5935/0103-507X.20220007-pt.

- [67] Yang TH, Chen KF, Gao SY, Lin CC. Risk factors associated with peri-intubation cardiac arrest in the emergency department. Am J Emerg Med. 2022;58:229–34. https://doi.org/10.1016/j.ajem.2022.06.013.
- [68] Russotto V, Tassistro E, Myatra SN, et al. Peri-intubation cardiovascular collapse in patients who are critically ill: insights from the INTUBE study. Am J Respir Crit Care Med. 2022;206(4):449–58. https://doi.org/10.1164/rccm.202111-2575OC.
- [69] April MD, Arana A, Schauer SG, et al. Ketamine versus etomidate and Peri-intubation hypotension: a National Emergency Airway Registry Study. Acad Emerg Med. 2020; 27(11):1106–15. https://doi.org/10.1111/acem.14063.
- [70] Broens SJL, Boon M, Martini CH, et al. Reversal of partial neuromuscular block and the Ventilatory response to hypoxia: a randomized controlled trial in healthy volunteers. Anesthesiology. 2019;131(3):467–76. https://doi.org/10.1097/ALN. 000000000002711.
- [71] Christensson E, Ebberyd A, Hårdemark Cedborg A, et al. Hypoxic ventilatory response after rocuronium-induced partial neuromuscular blockade in men with obstructive sleep apnoea. Anaesthesia. 2020;75(3):338–47. https://doi.org/10.1111/ anae.14806.
- [72] Martyn JAJ, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104 (1):158–69. https://doi.org/10.1097/00000542-200601000-00022.

- [73] Larach MG, Klumpner TT, Brandom BW, et al. Succinylcholine use and Dantrolene availability for malignant hyperthermia treatment: database analyses and systematic review. Anesthesiology. 2019;130(1):41–54. https://doi.org/10.1097/ALN. 000000000002490.
- [74] Guihard B, Chollet-Xémard C, Lakhnati P, et al. Effect of Rocuronium vs succinylcholine on endotracheal intubation success rate among patients undergoing out-ofhospital rapid sequence intubation: a randomized clinical trial. JAMA. 2019;322 (23):2303–12. https://doi.org/10.1001/jama.2019.18254.
- [75] Tran DTT, Newton EK, Mount VAH, Lee JS, Wells GA, Perry JJ. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev. 2015;2015(10):CD002788. https://doi.org/10.1002/14651858.CD002788.pub3.
- [76] Capone J, Gluncic V, Lukic A, Candido KD. Physiologically difficult airway in the patient with severe hypotension and metabolic acidosis. Case Rep Anesthesiol. 2020; 2020:8821827. https://doi.org/10.1155/2020/8821827.
- [77] De Jong A, Molinari N, Pouzeratte Y, et al. Difficult intubation in obese patients: incidence, risk factors, and complications in the operating theatre and in intensive care units. Br J Anaesth. 2015;114(2):297–306. https://doi.org/10.1093/bja/aeu373.